US20120323108A1 - Methods and apparatus for assessing activity of an organ and uses thereof - Google Patents

Methods and apparatus for assessing activity of an organ and uses thereof Download PDF

Info

Publication number
US20120323108A1
US20120323108A1 US13/494,429 US201213494429A US2012323108A1 US 20120323108 A1 US20120323108 A1 US 20120323108A1 US 201213494429 A US201213494429 A US 201213494429A US 2012323108 A1 US2012323108 A1 US 2012323108A1
Authority
US
United States
Prior art keywords
organ
voxels
activity
mean
computers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/494,429
Inventor
Robert G. Carroll
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
QUANTITATIVE IMAGING Inc
Original Assignee
QUANTITATIVE IMAGING Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by QUANTITATIVE IMAGING Inc filed Critical QUANTITATIVE IMAGING Inc
Priority to US13/494,429 priority Critical patent/US20120323108A1/en
Priority to US13/495,222 priority patent/US8938102B2/en
Assigned to QUANTITATIVE IMAGING, INC. reassignment QUANTITATIVE IMAGING, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CARROLL, ROBERT G.
Publication of US20120323108A1 publication Critical patent/US20120323108A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06TIMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T7/00Image analysis
    • G06T7/0002Inspection of images, e.g. flaw detection
    • G06T7/0012Biomedical image inspection
    • G06T7/0014Biomedical image inspection using an image reference approach
    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06TIMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T7/00Image analysis
    • G06T7/0002Inspection of images, e.g. flaw detection
    • G06T7/0012Biomedical image inspection
    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06TIMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T7/00Image analysis
    • G06T7/10Segmentation; Edge detection
    • G06T7/136Segmentation; Edge detection involving thresholding
    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06TIMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T2207/00Indexing scheme for image analysis or image enhancement
    • G06T2207/10Image acquisition modality
    • G06T2207/10072Tomographic images
    • G06T2207/10104Positron emission tomography [PET]
    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06TIMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T2207/00Indexing scheme for image analysis or image enhancement
    • G06T2207/30Subject of image; Context of image processing
    • G06T2207/30004Biomedical image processing
    • G06T2207/30016Brain

Definitions

  • This invention relates to methods and apparatus for imaging activity of an organ of a subject for diagnosis and prognosis of pathology or injury to the organ, where unaffected portions of the organ are used as a reference for assessing activity of afflicted areas of the organ.
  • Fluorine-18 deoxyglucose has proven to be a remarkably good way of tracing the level of physiological glucose metabolism in living cells. Uptake of fluorine-18 deoxyglucose is proportional to the number of glucose transporter 1 (GLUT1) receptors expressed on the cell surface. The number of GLUT1 receptors on the surface is regulated by the cell in accord with its level of internally sensed demand for glucose. Once FDG glucose enters the cell, further metabolism is prevented by the lack of oxygen within the constructor. Thus, one has an ideal physiological tracer for glucose uptake, separated from further intracellular stages of glucose metabolism. New and improved PET scanners continue to be developed (e.g., Shiga et al., 2009).
  • a voxel is a data point on a regular grid in three dimensional space.
  • a voxel i.e., a volumetric pixel, is analogous to a pixel, which represents two dimensional image data.
  • the data point can consist of a single piece of datum or multiple pieces of data.
  • Voxel-based morphometry is an imaging analysis technique that can be used to investigate focal differences in, for example, the brain between two groups of subjects (e.g., Ashburner and Friston, 2000).
  • Voxel-based morphometry studies have been carried out by comparing patients with controls, for example in studies of dementia (Mummery et al., 2000) and traumatic brain injury (Garcia-Panach et al., 2011).
  • control groups can impede the use of imaging for diagnosis. This is especially the case since there are, for example, gender-specific cerebral areas of age-associated changes of FDG uptake (Kim et al., 2009).
  • accurate diagnosis of diffuse axonal injury is severely limited by requirements for adequate age- and gender-matched control groups.
  • One widely used software program has only 4 patients below age 55; and only 37 patients in the 56-75 year age range as baseline controls. Other databases are even more lacking.
  • the present invention makes use of the normal portions of a patient's own organ to calculate baseline physiological function.
  • Using the patient as its own control creates far more powerful imaging and measurement statistics as well as greater reliability for the relevance of the measurements for the patient's own situation.
  • With use of the individual as its own control the available precision of measurement is vastly improved because one is not required to have a reference population of the same age or gender, or same manufacture or same generation of equipment, or precisely the same protocol of imaging in a reference population.
  • the present invention can provide improved technical features over the art.
  • the invention also provides systems for assessing the activity of an organ in a subject comprising one or more processors, a memory unit, and a computer-readable storage medium including computer-readable code that is read by the one or more processors to perform a method comprising the steps of: a) accessing by one or more computers a quantitative three-dimensional image of the organ that is represented as voxels, wherein each voxel contains information about the activity of a portion of the organ; b) calculating by the one or more computers a mean of the activity represented by the voxels, wherein voxels representing values at upper and lower extremes are excluded from calculation of the mean; c) calculating by the one or more computers a standard deviation of the mean obtained in step b), wherein voxels representing activity above a certain standard deviation of the mean indicate areas of the organ having increased activity and wherein voxels representing activity below a certain standard deviation of the mean indicate areas of the organ having reduced activity; and d) outputting by the one or more computers
  • the invention further provides systems for assessing the activity of an organ in a subject comprising: a) an imaging system comprising: i) an imaging device for generating a quantitative three-dimensional image of the organ that is represented as voxels, wherein each voxel contains information about the activity of a portion of the organ; and ii) a computing device operatively connected to the imaging device and to a first display device; and b) one or more computers operatively connected to the imaging system, comprising one or more processors, a memory unit, and a computer-readable storage medium including computer-readable code that is read by the one or more processors to perform a method comprising the steps of: i) receiving by the one or more computers the generated three-dimensional organ image; ii) calculating by the one or more computers a mean of the activity represented by the voxels, wherein voxels representing values at upper and lower extremes are excluded from calculation of the mean; iii) calculating by the one or more computers a standard
  • the invention still further provides systems for assessing the activity of an organ in a subject comprising: a) one or more computing devices comprising one or more processors, a memory unit, and a computer-readable storage medium including computer-readable code that is read by the one or more processors to perform a method comprising the steps of: i) obtaining by the one or more computing devices a quantitative three-dimensional image of the organ that is represented as voxels, wherein each voxel contains information about the activity of a portion of the organ generated by an imaging device; ii) transmitting the generated three-dimensional organ image to one or more analysis computing devices; iii) obtaining a representation of the organ from the one or more analysis computing devices, wherein the representation shows areas of the organ having increased activity and/or reduced activity; and iv) displaying the obtained representation on the display device.
  • FIG. 2 is a schematic representation illustrating a imaging system operatively connected to one or more computing devices according to an exemplary embodiment of the present disclosure.
  • FIG. 3 is a flow chart illustrating an exemplary method for assessing the activity of an organ in a subject according to an exemplary embodiment of the present disclosure.
  • FIGS. 4A-4D are exemplary charts showing results of various psychometrics tests performed with a subject over a one year period.
  • FIG. 5A-5B show comparative quantitative PET images showing significant improvement in Case Study #1 from May 2011 (A) to February 2012 (B) consistent with improved cognitive scores.
  • the invention may provide a method for assessing the activity of an organ in a subject with the aid of a digital computer comprising:
  • step b) calculating by the one or more computers a standard deviation of the mean obtained in step b), wherein voxels representing activity above a certain standard deviation of the mean indicate areas of the organ having increased activity and wherein voxels representing activity below a certain standard deviation of the mean indicate areas of the organ having reduced activity;
  • the method may comprise outputting by the one or more computers to the output device a representation of the organ showing areas of the organ having neither increased activity and/or reduced activity.
  • the invention may provide a system for assessing the activity of an organ in a subject comprising one or more processors, a memory unit, and a computer-readable storage medium including computer-readable code that is read by the one or more processors to perform a method comprising the steps of:
  • step b) calculating by the one or more computers a standard deviation of the mean obtained in step b), wherein voxels representing activity above a certain standard deviation of the mean indicate areas of the organ having increased activity and wherein voxels representing activity below a certain standard deviation of the mean indicate areas of the organ having reduced activity;
  • the system may comprise outputting by the one or more computers to the output device a representation of the organ showing areas of the organ having neither increased activity and/or reduced activity.
  • voxels representing values at upper and lower extremes from the calculation of the mean.
  • voxels can be excluded from calculation of the mean if the voxels represent values at the upper and lower 1%, 5% or 10% of the values.
  • a first mean can be calculated of the activity represented by all the voxels. Then, voxels representing values at the upper and lower values can be excluded, either if the values are above or below a certain percentage of all values or if the values are above or below a certain standard deviation of the first mean. The voxels that are not excluded are then used to calculate a new mean of normal voxels.
  • Another method of excluding vowels that represent outlier values is to construct a histogram of values represented by all voxels, then fitting a curve to the histogram, and excluding voxels that deviate above or below the curve. These procedures can be performed by the one or more computers that calculated a mean of the activity represented by the voxels where voxels representing values at upper and lower extremes are excluded from calculation of the mean.
  • Standard deviation (SD) of the mean can be expressed, for example in 1SD, 0.1 SD or 0.01 SD units.
  • SD can be calculated in 0.01 or 0.1 SD units between 3.0, 3.5, 4.0 or 4.5 SD units below the mean to 3.0, 3.5, 4.0 or 4.5 SD units above the mean.
  • standard deviation (SD) is calculated in 0.1 SD units between 4.0 SD units below the mean to 4.0 SD units above the mean.
  • a threshold can be set at 1.0 SD, 1.5 SD, 1.65 SD, 2.0 SD, 2.5 SD, 3.0, 3.5, 4.0 or 4.5 SD units above or below the mean.
  • voxels representing activity above 1.5 SD units above the mean indicate areas of the organ having increased activity and voxels representing activity below 1.5 SD units below the mean indicate areas of the organ having reduced activity.
  • Other variations can be used consistent with the letter and spirit of the present disclosure.
  • the organ from which the image is obtained can be, for example, brain, heart, lung, kidney, liver, pancreas, bladder, salivary glands, esophagus, stomach, gallbladder, intestines, colon, rectum, thyroid, parathyroid, adrenal gland, ureter, bladder, urethra, tonsils, adenoids, thymus, spleen, ovary, fallopian tube, uterus, vagina, mammary gland, testes, vas deferens, seminal vesicle, prostate, penis, pharynx, larynx, trachea, bronchi or lung, to name a few.
  • the image of the organ can be obtained using, for example, positron emission tomography (PET), functional magnetic resonance imaging (fMRI), any type or sequence of magnetic resonance imaging (MRI) including diffusion tensor magnetic resonance imaging, single photon emission computed tomography (SPECT), magnetic source imaging or optical imaging, to name a few.
  • PET positron emission tomography
  • fMRI functional magnetic resonance imaging
  • MRI magnetic resonance imaging
  • SPECT single photon emission computed tomography
  • magnetic source imaging or optical imaging to name a few.
  • three dimensional imaging of the organ can be obtained using positron emission tomography (PET) in connection with a computed tomography (CT) X-ray scan, or may be obtained using positron emission tomography (PET) in connection with any magnetic resonance scan.
  • CT computed tomography
  • PET positron emission tomography
  • Dedicated brain-only solid-state PET scanners are being developed by Hitachi. Such units may provide essential physiological information for a much lower patient radiation dose than existing PET CT machines.
  • a PET CT general-purpose machine may generate a CT dose 10 times the radiation dose from a 15 milicurie FDG injection.
  • the dedicated machine entirely does away with the CT dose and drops the required FDG dose by factor of five to about 3 mCi. In exemplary embodiments, such dedicated machines and the like can be used.
  • areas of increased or reduced activity in an organ can indicate a disease, an injury, a response to an injury, or functional changes in areas that have been disconnected from the remainder of the brain or spinal cord because of injury to connective structures.
  • diseases or injuries include a tumor, stroke, infection, demyelinating disease, degenerative disease, dementia, ischemia, traumatic injury, shock wave injury, or primary or metastatic cancer, to name a few.
  • areas of reduced activity can represent diffuse axonal injury, and/or represent areas of the brain disconnected from their source of workload.
  • Functional connectivity MRI can be used to show which parts of the brain are communicating.
  • areas of disease or injury can be further analyzed by determining a ratio of a number of voxels showing increased activity to a number of voxels showing decreased activity within the area of disease or injury. Further analysis can include determining a ratio of a number of voxels showing increased activity to a number of voxels showing decreased activity within the entirety of a diseased area and/or at a border region between an area of disease or injury and normal tissue.
  • an image of the organ can be obtained and analyzed at a plurality of time points. Images obtained at different time points can be used, for example, to evaluate effectiveness of a course of treatment of a subject or to evaluate progression of disease.
  • an image of the brain can be obtained and analyzed at a plurality of time points during neurological surgery or during neurological intensive care.
  • Frequent serial brain PET studies can be used to guide neurological surgery and neurological intensive care of brain injured patients.
  • periodic, or non-periodic repeated assessments may provide a tool for demonstrating response to therapy in a timely manner.
  • studies may be repeated, e.g., a minimal interval of about three hours to a more common interval of daily, weekly, monthly, to name a few, to document brain glucose metabolism, brain oxygen metabolism, brain blood flow, and other vital parameters, to name a few.
  • Some neurological surgery procedures have operating room durations in excess of 10 hours. Neurological intensive care can last for months.
  • an image of the heart can be obtained and analyzed at a plurality of time points during cardiac surgery, during cardiac interventional procedures, and/or during cardiac intensive care.
  • frequent serial heart PET studies can be used to guide cardiac surgery and cardiac interventional intensive care of heart injured patients.
  • Periodic and/or non-periodic repeated assessments may provide a tool for demonstrating response to therapy in a timely manner. Studies may be repeated, e.g., a minimal interval of about 5 minutes to a more common interval of daily, weekly, monthly, to name a few, to document cardiac nutritional blood flow using rubidium 82, cardiac FDG metabolism using fluorine 18; cardiac oxygen metabolism using oxygen 15, and other vital parameters, to name a few.
  • Voxels within an area of disease or injury in the organ can be analyzed at a plurality of time points, and a ratio of a number of voxels within the area showing increased activity over time to a number of voxels within the area showing decreased activity over time can be used as a measure of whether the disease or injury is improving or not improving.
  • a ratio of a number of voxels within the area showing increased activity over time to a number of voxels within the area showing decreased activity over time can be used as a measure of whether the disease or injury is improving or not improving.
  • the disease is cancer
  • a decrease in the ratio of the number of voxels within the area of disease showing increased activity over time to the number of voxels within the area of disease showing decreased activity over time is indicative of a favorable outcome.
  • an increase in the ratio of the number of voxels within the area showing increased activity over time to the number of voxels within the area showing decreased activity over time is indicative of a favorable outcome.
  • the subject can be any living organism, including any type of animals, such as humans.
  • the methods disclosed herein can comprise imaging the subject to obtain an image of the organ.
  • a system for assessing the activity of an organ in a subject may comprise:
  • an imaging system comprising:
  • an imaging device for generating a quantitative three-dimensional image of the organ that is represented as voxels, wherein each voxel contains information about the activity of a portion of the organ;
  • a computing device operatively connected to the imaging device and to a first display device
  • one or more computers operatively connected to the imaging system, comprising one or more processors, a memory unit, and a computer-readable storage medium including computer-readable code that is read by the one or more processors to perform a method comprising the steps of:
  • iii) calculating by the one or more computers a standard deviation of the mean obtained in step ii), wherein voxels representing activity above a certain standard deviation of the mean indicate areas of the organ having increased activity and wherein voxels representing activity below a certain standard deviation of the mean indicate areas of the organ having reduced activity;
  • the method performed by the one or more processors can comprise displaying by the one or more computers the generated representation of the organ on a second display device operatively connected to the one or more computers.
  • the method performed by the one or more processors can also comprise transmitting from the one or more computers the generated representation of the organ to the imaging system so as to be displayed on the first display device.
  • the image of the organ can obtained using, e.g., positron emission tomography (PET), functional magnetic resonance imaging (fMRI), any type or sequence of magnetic resonance imaging including diffusion tensor imaging (MRI); magnetic source imaging, optical imaging, computed tomography (CT) X-ray scan, or combinations thereof, to name a few.
  • PET positron emission tomography
  • fMRI functional magnetic resonance imaging
  • MRI diffusion tensor imaging
  • CT computed tomography
  • the image of the organ may be obtained using positron emission tomography (PET), alone, or in combination with CT or MRI.
  • a system for assessing the activity of an organ in a subject comprising one or more computing devices may comprise one or more processors, a memory unit, and a computer-readable storage medium including computer-readable code that is read by the one or more processors to perform a method comprising the steps of:
  • the representation of the organ can be generated using the transmitted three-dimensional organ image at the one or more analysis computers by a method comprising, e.g., the steps of:
  • step ii) calculating a standard deviation of the mean obtained in step i), wherein voxels representing activity above a certain standard deviation of the mean indicate areas of the organ having increased activity and wherein voxels representing activity below a certain standard deviation of the mean indicate areas of the organ having reduced activity.
  • a voxel analysis of the patient's own organ can be used to establish mean voxel values.
  • Median and mode voxel values can also be determined.
  • VBM voxel-based morphometric
  • a histogram may be provided, ranging from ⁇ 4 standard deviations to +4 standard deviations, for example, in 0.1 standard deviation steps illustrating the distribution of voxels within the boundaries of the organ being examined.
  • This histogram display of voxels can be used to select those voxels which will be statistically analyzed and graphically displayed. In a normal organ one expects a Gaussian distribution of voxels.
  • voxels can be analyzed using, for example, commercially available software such as provided by MIM Software Inc. (Cleveland, Ohio).
  • volumetric three-dimensional outlines of clusters can be viewed in a cinematic mode, for example, proceeding from ⁇ 4 standard deviations toward ⁇ 1 standard deviation thereby showing areas of each degree of damage.
  • a cinematic review of +3 standard deviation volumetric three-dimensional outlines allows demonstration of compensatory increase in neuronal function of undamaged structures and other recruited pathways. Such analysis can further verify the reality of damaged tissue by demonstrating the reality of compensatory mechanisms.
  • different indicia such as color overlays, text labels, boundary outlines or the like may be applied to the visual display output.
  • the display output can be a computer monitor but may also be high resolution printers as well, or other display devices. Three-dimensional volumetric displays of medical data are becoming increasingly available.
  • the invention may include the ability to generate a short, cycling presentation of the identified voxels (inactive and/or compensatory) at a plurality of standard deviations.
  • This cycling presentation or animation may be presented in three-dimensional contours of the organ. Three-dimensional contours of details of degree of metabolism within areas of damage can be simultaneously displayed.
  • the number of voxels within the three-dimensional boundaries defined by standard deviations such as, for example, 3, 2.5, 2.0, 1.5, and 1.0 standard deviations above or below the mean of non-involved tissue within that patients organ can be mapped over time to provide a very sensitive analysis of response to therapy versus progression of disease.
  • the brain quantitative analysis program may automatically cycle from the lowest transaxial slice to the highest transaxial slice.
  • the thickness of the slice can be adjusted from 4 mm to 20 mm.
  • Exemplary embodiments of the present disclosure may be applicable to a large range of noninvasive imaging modalities that can be used to address and quantitate changes in tissue physiology repair and disease processes over time.
  • clusters of voxels may be defined by deviants from the mean and can clearly show both the epicenter, the umbra and the penumbra of any imaginable physiological deviance within any organ, and may be measured by any modality that is voxel-based.
  • imaging MRI, functional MRI, diffusion tensor MRI, and other experimental MRI sequences may be candidates for such analysis.
  • such modalities may include positron emission tomography, magnetic resonance imaging, single photon emission computed tomography, CT, volumetric ultrasound, optical tissue imaging, and all other means of noninvasive volumetric imaging of living tissues.
  • symmetrical organs such as brain and kidneys
  • comparison can be made with the corresponding area in the contralateral side, bearing in mind that within the brain, the contralateral structure may be up-regulated to compensate for decreased function in the injured structure.
  • diffuse axonal injuries in the brain may generally appear as scattered small areas of decreased glucose metabolism on the gyri of the cerebral cortex. These lesions may be almost impossible to visually identify because of their location on a variable terrain.
  • voxel-based threshold imaging may clearly identify small scattered lesions.
  • objective quantification of the number, size, severity, and location of, for example, areas of decreased glucose metabolism within the brain may be possible without the need of a control group.
  • possible artifacts generated by arbitrary brain deformation may be avoided.
  • serial quantification of number, size, severity and location of injured areas may provide objective documentation of quantitative response to therapy. For example, therapies such as drug intervention and rehabilitation intervention can be compared with the spontaneous natural history of the untreated pathological process.
  • amyloid protein is commonly deposited at areas of injury, potentially leading to progressively greater injury over time due to amyloid toxicity.
  • amyloid brain imaging may be a natural adjunct to fluorine 18 deoxyglucose brain imaging in traumatic brain injury.
  • baseline measurements may be made on individuals involved in contact sports who can be tracked season by season.
  • the present invention can be used to identify the vulnerable post-concussion time during which repeated trauma can produce disproportionate severe damage.
  • Military personnel can be screened for susceptibility to additional blast injury predeployment, potentially decreasing the total number of individuals whose cumulative brain damage renders them nonfunctional. Most individuals have a degree of cognitive reserve which masks the behavioral and neurological signs and symptoms of lesser degrees of brain injury.
  • adjacent voxels may include volumes of cells with improving metabolism adjacent to volumes of cells with declining metabolism.
  • the ratio of voxels advancing to voxels declining may be a measure of whether the overall physiology is favoring regeneration or death.
  • whether the process is cancer where one wants the decline to be predominant or areas of blocked blood flow where one wants the advance to be predominant progress of the local physiological condition can be objectively measured in a timely fashion to allow therapeutic intervention with near real-time monitoring of the results. This may allow one to measure the status of the region, intervene therapeutically, and then remeasure.
  • each patient, and each area of brain hypometabolism may require frequent monitoring to detect the local advance decline ratio.
  • each patient and each area of brain hypometabolism may have differing dose response curves for any therapeutic intervention.
  • the ratio of the number of voxels improving/number of voxels worsening in an anatomical area can provide a unique measure of overall disease progression and treatment effectiveness over time.
  • the border between normal and abnormal tissue areas may be another region of interest.
  • the number of voxels in each degree of deviance from the mean may be obtained, and serial images may be displayed, such as, for example, starting with those voxels that are most negative ( ⁇ 4 standard deviations). Further, the obtained voxels may be summed with all interval voxels to a selected endpoint, such as, for example, ⁇ 1.65 standard deviations.
  • This may produce a quantitative three-dimensional volumetric map of the range of disease.
  • This map may be electronically saved on any suitable computer-readable storage device and subsequently used to quantitatively compare with a second volumetric map obtained after therapy in accordance with the expected time course of disease resolution. For example, the second map may be obtained one to three months after therapy relating to chronic conditions. In other situations, the second map may be obtained one to three days after therapy relating to acute conditions.
  • the quantitative disease assessment taking place at regular intervals may serve as an objective measurement of the efficacy of any drug or interventional therapy.
  • any drug or interventional therapy For example, in a laboratory or a clinical research setting more frequent observations can document the physiology of the repair sequence.
  • surrogate markers for pharmacological intervention trials may be validated. These can be of immense help in drug discovery. These can also be of immense help in determining whether an individual patient is benefiting from the intervention. Non-responders can be spared potential toxicity that is not offset by benefit.
  • a histogram display of all of the voxels within the defined boundaries of a disease process within a specific anatomical area may be provided.
  • an area of traumatic brain injury in the right frontal lobe may contain 500,000 voxels. 100,000 of these voxels may be located within plus and minus 1 millimeter of the transition zone from affected tissue to normal tissue, the apparent visual boundary of the disease process. The 100,000 voxels in the transition zone will be expected to display a wide range of metabolic uptake values. The voxels which are more centrally located will also be expected to exhibit a wide range of metabolic uptake values. All of the voxels within the visual boundary of the disease process are likely to change metabolic uptake over time as the cells improve or die.
  • a software product may be used for detecting diffuse axonal injuries in a brain.
  • the software product may be any suitable computer-readable storage media that contains instructions, that when executed, cause one or more computers to perform the steps: accessing a digital brain scan of a subject's entire brain; quantitatively identifying voxels having inactivity of, e.g., ⁇ 1.65 standard deviations or less from that of the entire brain, or activity of, e.g.
  • FIG. 1 shows, according to an exemplary embodiment, a method for detecting diffuse axonal injuries.
  • a volumetric digital brain scan image of a subject's entire brain may be obtained or accessed.
  • voxels may be quantitatively identified which are, e.g., ⁇ 1.5 standard deviations or less from that of the entire brain which may indicate inactivity and/or are, e.g., +1.5 standard deviations or more from the entire brain which may indicate compensatory activity.
  • one or more threshold values may be established for localizing one or more clusters of said identified voxels.
  • a clustering algorithm may be applied to localize said one or more clusters using the one or more threshold values.
  • the clustering algorithm may be applied to the identified voxels above or below the 1.5 standard deviations from the brain.
  • one or more indicias may be generated with respect to the one or more sets of identified clusters.
  • a revised digital brain scan image with visually perceptible indicia associated may be generated.
  • a revised digital brain scan image may be displayed on an output device.
  • alternative pathways to and from the areas of identified areas of compensatory activity may be stimulated.
  • the method as illustrated in FIG. 1 may further comprise the steps of: accessing a digital brain scan image of a subject's entire brain; quantitatively identifying voxels having inactivity of at a plurality of standard deviations less than, e.g., ⁇ 1.0; establishing a threshold value for localizing one or more clusters of said identified voxels; applying a clustering algorithm to localize said one or more clusters; sequentially generating a plurality of revised digital brain scan images with visually perceptible indicia associated with said one or more clusters localized at each standard deviation value; and displaying said revised digital brain scan image on an output device.
  • diffuse axonal injuries may be detected in a brain by implementing a method comprising the steps of: accessing a digital brain scan image of a subject's entire brain; quantitatively identifying voxels having compensatory activity of at a plurality of standard deviations greater than, e.g., 1.0; establishing a threshold value for localizing one or more clusters of said identified voxels; applying a clustering algorithm to localize said one or more clusters; sequentially generating a plurality of revised digital brain scan images with visually perceptible indicia associated with said one or more clusters localized at each standard deviation value; and displaying said revised digital brain scan images on an output device.
  • the revised digital brain scan images may be presented in three-dimensional contours.
  • FIG. 2 shows an imaging system, generally designated by number 5 .
  • the imaging system 5 may include one or more imaging devices designated by number 10 , that may be operatively connected to one or more computing devices generally designated by number 20 .
  • the imaging device 10 may generate an quantitative three-dimensional image of an organ, such as, for example, a brain, heart, lung, kidney, liver, pancreas, bladder, salivary glands, esophagus, stomach, gallbladder, intestines, colon, rectum, thyroid, parathyroid, adrenal gland, ureter, bladder, urethra, tonsils, adenoids, thymus, spleen, ovary, fallopian tube, uterus, vagina, mammary gland, testes, vas deferens, seminal vesicle, prostate, penis, pharynx, larynx, trachea, bronchi and lung, to name a few.
  • an organ such as, for example, a brain,
  • the image of the organ may be generated using positron emission tomography (PET), computed tomography (CT) X-ray scan, functional magnetic resonance imaging (fMRI), magnetic source imaging or optical imaging, or combinations thereof.
  • PET positron emission tomography
  • CT computed tomography
  • fMRI functional magnetic resonance imaging
  • magnetic source imaging or optical imaging or combinations thereof.
  • the three-dimensional imaging maybe obtained using a PET scan in connection with a CT X-ray scan.
  • the imaging system 10 may be operatively connected to one or more computer networks 50 , such as, for example, the Internet, or any other suitable network, via, by way of example, a set of routers and/or networking switches.
  • the imaging system 10 may be connected to an imaging analysis system 30 or any one of its components.
  • the imaging analysis system 30 may include one or more analysis computers, designated by number 40 .
  • the analysis computers 40 may include one or more processors, computer readable storage media, and memory units.
  • the one or more processors may read and execute software embodied as instructions stored on the computer readable storage media, according to exemplary embodiments herein.
  • the analysis system 30 may be used to assess the activity of organ.
  • the analysis computers 40 may obtain a image scan of an organ.
  • the organ may be from an animal, including a human.
  • the image scan data generated by the imaging device 10 may be sent directly or indirectly to the analysis system 30 .
  • the obtained image scan may be a quantitative three-dimensional image of the organ.
  • This image or image scan may include voxels or voxel data, wherein each voxel contains information about the activity of a portion of the imaged organ.
  • the imaging device 10 may generate a PET scan of the organ in a Digital Imaging and Communications in Medicine (DICOM) format.
  • the image or scan data may contain at least four elements as follows: an x coordinate, a y coordinate, a z coordinate, and a value measured at the x, y, and z coordinates. Since DICOM is a standard covering both data formats and protocols for communications, the image scan/data may be obtained several ways. See DICOM at: http://en.wikipedia.org/wiki/DICOM.
  • the obtained image scan may be used by the analysis computers 40 to calculate activity using the voxels.
  • the mean of the activity represented by the voxels may be calculated.
  • voxels representing extreme upper and lower values may be excluded.
  • Voxels representing values at the upper and/or lower 1%, 5%, 10%, or any other appropriate voxels representing values in an extreme range may be excluded.
  • the analysis computers 40 may further, based on the calculated mean, calculate one or more voxel threshold values.
  • the analysis computers 40 may calculate a standard deviation using the calculated mean.
  • the standard deviation may be calculated in 0.1 standard deviation (SD) units between 4.0 SD units below the mean to 4.0 SD units above the mean.
  • the standard deviation may be calculated in 0.01 standard deviation (SD) units.
  • the standard deviation may be calculated in units between 3.0 SD units below the mean to 3.0 SD units above the mean.
  • the analysis computers may determine voxels are outside or beyond the calculated threshold values.
  • the analysis computers 40 may determine voxels which are a specified standard deviation above or below the mean, as such voxels may respectively indicate areas of the organ with increased or decreased activity. For example, voxels representing activity 1.65 SD units above or below the mean may indicate, respectively, increased or decreased activity. In some exemplary embodiments, other standard deviation unit values may be used to indicate activity/inactivity. For example, voxels representing activity anywhere from 1.00-4.00 SD units above or below the mean may indicate increased or decreased activity.
  • the calculated data regarding the voxels may be stored, such as in databases 35 , for future use.
  • a representation of the organ based on the calculations performed by the analysis computers 40 , may be outputted to an output device to show the areas of the organ with increased and/or decreased activity.
  • the analysis computers 40 may be connected to a display device to display the representation of the organ.
  • the displayed representation may be a histogram.
  • software such as the MIMneuro may be used at least by the analysis computers 40 to perform one or more of the calculations and generate a representative output based on such calculations, such as for example a histogram.
  • the representation of the output representation of the organ showing increased/decreased activity may be sent from the analysis computers 40 to the imaging system 10 .
  • the output representation may be displayed a on a display operatively connected to the computer 20 .
  • the imaging device 10 and/or computer may be located any suitable locations, such as, for example, a doctor's office, a hospital, a clinic, to name a few.
  • the output representation and associated calculations related to the organ may be used by a physician.
  • a physician may observe a representation, such as histogram of the organ scan.
  • the physician may select a range of histogram bars representing voxel values that are a certain amount of standard deviations away from the mean for the entire organ scan, such as for example, 1.5 SD units, 1.65 units, to an name a few.
  • such a selection may be symmetrical about the mean. For instance, if a large count of voxels (i.e. a spike) occurs at ⁇ 1.3 standard deviations, then something less than 1.3 standard deviations will be selected as the “normal range” both above the mean and below the mean, and equidistant from the mean.
  • the physician may perform a visual verification of the normal area.
  • the analysis computers 40 or computer 20 may be used to display a visual map of the scan data that highlights the “normal area” as a result the physician's selection. If the selection verifies, then the mean, median and mode may be calculated and stored for future comparisons.
  • areas of increased or reduced activity in the organ indicate a disease or an injury, such as, for example, a tumor, stroke, infection, demyelinating disease, degenerative disease, dementia, ischemia, traumatic injury, or primary or metastatic cancer, to name a few.
  • a disease or an injury such as, for example, a tumor, stroke, infection, demyelinating disease, degenerative disease, dementia, ischemia, traumatic injury, or primary or metastatic cancer, to name a few.
  • areas of reduced activity in the organ may represent diffuse axonal injury.
  • Further processing regarding the voxels may include rescaling the voxels and calculating an advance/decline ratio.
  • the voxels may be rescaled so as to eliminate any biases, with any scaled data and/or scaling factors may be stored for future reference.
  • the advanced/decline ratio may also be stored for future reference.
  • the voxels from one side of the imaged organ may be compared with the corresponding voxels on the opposite side of the same organ.
  • voxels from one organ on side of the body may be compared with corresponding voxels on the corresponding organ on the opposite side of the body.
  • Analyses preformed using the voxels may include determining a ratio of a number of voxels showing increased activity to a number of voxels showing decreased activity at a border region between an area of disease or injury and normal tissue.
  • the process of accessing organ activity as illustrated in FIG. 2 may be repeated over a period of time at certain intervals so as to determine any changes in activity.
  • an image of the organ may obtained and analyzed at a plurality of time points.
  • the images obtained at different time points may be used to evaluate effectiveness of a course of treatment of a subject or to evaluate progression of disease.
  • the voxels within an area of disease or injury in the organ may be analyzed at a plurality of time points and a ratio of a number of voxels within the area showing increased activity over time to a number of voxels within the area showing decreased activity over time may be a measure of whether the disease or injury is improving or not improving.
  • psychometric tests may be used in addition or in conjunction with to assess and/evaluate the brain and its activity.
  • a plurality of psychometric tests may also be administered with respect to the patient over the same period of time.
  • various things may be tracked, such as for example, the absolute number of voxels, the advanced/decline ratio, and the percentage of activity change in certain areas, to name a few.
  • FIGS. 4A-4B shows results of various psychometric tests that may administered over a 1 year time period.
  • RM a 46 year old male suffered traumatic brain injury when he fell on his head from a loft, a distance of 8 feet in February 1997.
  • the patient was severely incapacitated, declared totally and permanently disabled by Social Security and was evaluated at Mayo Clinic Jacksonville. With remarkable persistence in a self-directed rehabilitation program, he was able to resume gainful employment after several years. Subsequently, the patient reported hitting his head from a major bicycle accident and hitting his head when he walked into an obstruction at a warehouse.
  • the patient had been self-medicating with alcohol and had stopped self-directed rehabilitation.
  • Comparative Quantitative Imaging showed significant improvement from May 2011 to February 2012 consistent with improved Cognitive scores (Table 1). Significant improvement is noted especially in frontal lobes.
  • FIG. 5A the patient's brain is imaged showing areas 501, 502, 503, 504, and 505 with decreased activity.
  • FIG. 5B shows the imaged brain in February 2012, with improvement in those same areas.
  • RM has had about seventy 1.3 atmosphere hyperbaric treatments since November, 2011. Patient reports mediation 3 to 5 times a week, no drinking, and consistent vitamin B complex use since Nov. 26, 2011. His family and economic stress level are twice as high as compared to a year ago. RM has shown remarkable improvement in frontal lobe PET scan hypometabolism, remarkable improvement in Processing Speed, and significant improvement in Neurocognitive Index.
  • Cortical confluent hypometabolic areas are seen at the base of the brain centering on the brainstem, pons, cerebellar vermis and cerebellar peduncles.
  • the inferior aspects of cortical and subcortical regions of both temporal lobes are hypometabolic; the medial aspects of both cerebellar hemispheres are involved; there is also significant spotty cortical and subcortical hypometabolism of the inferior aspects of the frontal lobes.
  • Midline images of the brain demonstrate severe extensive hypometabolism of the basal ganglia and midbrain.
  • hypometabolic area measuring 2.3 cm in height by 0.7 cm in width involving much of the left superior frontal gyms.
  • Hypometabolism is extensive in the left orbitofrontal region including the medial orbital gyms.
  • the left anteriororbital gyms is hypometabolic.
  • the right inferior medial frontal gyms is hypometabolic; left superior frontal gyms measuring 0.7 cm diameter is severely hypometabolic, left middle frontal gyms is hypometabolic.
  • Left supplementary motor area is extensively hypometabolic.
  • Left middle frontal gyms is hypometabolic.
  • Left superior frontal gyms is hypometabolic; left precentral gyms is hypometabolic; left superior frontal gyms is hypometabolic.
  • the left superior medial frontal gyms is severely hypometabolic measuring 2 cm in anterior-posterior dimension and about 1.5 cm in width.
  • Right fusiform gyms is extensively hypometabolic; right hippocampus is extensively hypometabolic measuring 2.9 cm in height by 1.3 cm in width by 4.4 cm in oblique anterior-posterior length.
  • Right temporal pole is hypometabolic.
  • the left temporal pole is hypometabolic; the left fusiform gyms is involved.
  • the left hippocampus is significantly hypometabolic.
  • the right rolandic operculum is hypometabolic;
  • the right super marginal gyms is hypometabolic.
  • the right precentral gyms is hypometabolic.
  • the right posterior cingulate gyms is hypometabolic.
  • the right superior parietal lobule is extensively hypometabolic.
  • the right precentral gyms is hypometabolic.
  • the right superior parietal lobule is extensively and severely hypometabolic.
  • the right angular gyms is hypometabolic as is the right supra-marginal gyms.
  • the left rolandic operculum is hypometabolic.
  • the left super marginal gyms is hypometabolic; the left precentral gyms is hypometabolic; the left postcentral gyms is hypometabolic; left superiorparietal lobule is hypometabolic; the left pre-post central gyms is hypometabolic; the left superior parietal lobule is very extensively and severely hypometabolic.
  • Left supra marginal gyms is hypometabolic.
  • Left angular gyms is hypometabolic.
  • Basal Ganglia
  • the putamen is hypometabolic bilaterally.
  • the globis pallidus bilaterally is extensively hypometabolic.
  • the right thalamus is severely hypometabolic measuring about 3 cm in height by 2.1 cm in anterior-posterior dimension.
  • Left thalamus is severely hypometabolic measuring 4.2 cm in height by 2.2 cm in width.
  • the right superior occipital gyms shows extensive hypometabolism. There is definite involvement of the right primary visual cortex. The right lingual gyms inferior to the right primary visual cortex is also severely hypometabolic.
  • the left primary visual cortex There is definite involvement of the left primary visual cortex measuring 2.3 cm in height by 1.3 cm in width, by 2.6 cm in anterior-posterior dimension. There is very extensive involvement of the left primary visual cortex.
  • the left superior occipital gyms has extensive hypometabolism. Adjacent structures in the left occipital lobe are also hypometabolic.
  • the left lingual gyms is hypometabolic and the right superior occipital gyms is hypometabolic; the right fusiform gyms is hypometabolic.
  • the left fusiform gyms and left inferior occipital gyms are focally hypometabolic
  • This patient demonstrates extensive severe traumatic brain injury in both the right and left sides of his brain.
  • Very severe memory impairment is directly traceable to hypometabolism in both hippocampi, and bilaterally in the thalamus.
  • Visual difficulties are directly traceable to bilateral hypometabolism in the primary visual cortex.
  • Difficulties with emotional self-regulation are directly correlated with hypometabolism in both amygdala, as well as extensive areas of hypometabolism in the frontal cortex bilaterally.

Abstract

Methods and apparatus are provided for imaging activity of an organ of a subject for diagnosis and prognosis of pathology or injury to the organ, where unaffected portions of the organ are used as a reference for assessing activity of afflicted areas of the organ.

Description

    CROSS-REFERENCE TO RELATED APPLICATION
  • This application claims the benefit of U.S. Provisional Patent Application No. 61/498,243, filed on Jun. 17, 2011, the content of which is incorporated herein by reference in its entirety.
  • FIELD
  • This invention relates to methods and apparatus for imaging activity of an organ of a subject for diagnosis and prognosis of pathology or injury to the organ, where unaffected portions of the organ are used as a reference for assessing activity of afflicted areas of the organ.
  • BACKGROUND
  • Throughout this application various publications are referred to in parenthesis. Full citations for these references may be found at the end of the specification immediately preceding the claims. The disclosures of these publications are hereby incorporated by reference in their entireties into the subject application to more fully describe the art to which the subject application pertains.
  • Nuclear medicine involves the noninvasive quantification of physiological processes. In the case of positron emission tomography (PET), fluorine-18 deoxyglucose (FDG) has proven to be a remarkably good way of tracing the level of physiological glucose metabolism in living cells. Uptake of fluorine-18 deoxyglucose is proportional to the number of glucose transporter 1 (GLUT1) receptors expressed on the cell surface. The number of GLUT1 receptors on the surface is regulated by the cell in accord with its level of internally sensed demand for glucose. Once FDG glucose enters the cell, further metabolism is prevented by the lack of oxygen within the constructor. Thus, one has an ideal physiological tracer for glucose uptake, separated from further intracellular stages of glucose metabolism. New and improved PET scanners continue to be developed (e.g., Shiga et al., 2009).
  • Imaging studies have been used between groups of subjects to demonstrate evidence of injuries or pathologies (e.g., Kato et al., 2007; Zhang et al., 2010). Three dimensional images can be represented using voxels. A voxel is a data point on a regular grid in three dimensional space. A voxel, i.e., a volumetric pixel, is analogous to a pixel, which represents two dimensional image data. The data point can consist of a single piece of datum or multiple pieces of data. Voxel-based morphometry is an imaging analysis technique that can be used to investigate focal differences in, for example, the brain between two groups of subjects (e.g., Ashburner and Friston, 2000). Voxel-based morphometry studies have been carried out by comparing patients with controls, for example in studies of dementia (Mummery et al., 2000) and traumatic brain injury (Garcia-Panach et al., 2011).
  • The need for control groups can impede the use of imaging for diagnosis. This is especially the case since there are, for example, gender-specific cerebral areas of age-associated changes of FDG uptake (Kim et al., 2009). For example, accurate diagnosis of diffuse axonal injury is severely limited by requirements for adequate age- and gender-matched control groups. One widely used software program has only 4 patients below age 55; and only 37 patients in the 56-75 year age range as baseline controls. Other databases are even more lacking. Thus, it is impossible to objectively measure brain injury in those groups of individuals most prone to brain injury, i.e., infants, children, adolescents, athletes of age 15 to 30 and motor vehicle accident survivors aged 15 to 55. Data in those younger than 15 are very scarce.
  • The prevent invention address the need for a method of imaging injuries and pathologies that does not require comparison of a patient to a control group of subjects.
  • SUMMARY
  • In exemplary embodiments, the present invention makes use of the normal portions of a patient's own organ to calculate baseline physiological function. Using the patient as its own control creates far more powerful imaging and measurement statistics as well as greater reliability for the relevance of the measurements for the patient's own situation. With use of the individual as its own control, the available precision of measurement is vastly improved because one is not required to have a reference population of the same age or gender, or same manufacture or same generation of equipment, or precisely the same protocol of imaging in a reference population. Thus, the present invention can provide improved technical features over the art.
  • In exemplary embodiments, the invention provides methods for assessing the activity of an organ in a subject with the aid of a digital computer comprising: a) accessing by one or more computers a quantitative three-dimensional image of the organ that is represented as voxels, wherein each voxel contains information about the activity of a portion of the organ; b) calculating by the one or more computers a mean of the activity represented by the voxels, wherein voxels representing values at upper and lower extremes are excluded from calculation of the mean; c) calculating by the one or more computers a standard deviation of the mean obtained in step b), wherein voxels representing activity above a certain standard deviation of the mean indicate areas of the organ having increased activity and wherein voxels representing activity below a certain standard deviation of the mean indicate areas of the organ having reduced activity; and d) outputting by the one or more computers to an output device a representation of the organ showing areas of the organ having increased activity and/or reduced activity. In some exemplary embodiments, the method may further comprise outputting by the one or more computers to the output device a representation of the organ showing areas of the organ having neither increased activity and/or reduced activity.
  • In exemplary embodiments, the invention also provides systems for assessing the activity of an organ in a subject comprising one or more processors, a memory unit, and a computer-readable storage medium including computer-readable code that is read by the one or more processors to perform a method comprising the steps of: a) accessing by one or more computers a quantitative three-dimensional image of the organ that is represented as voxels, wherein each voxel contains information about the activity of a portion of the organ; b) calculating by the one or more computers a mean of the activity represented by the voxels, wherein voxels representing values at upper and lower extremes are excluded from calculation of the mean; c) calculating by the one or more computers a standard deviation of the mean obtained in step b), wherein voxels representing activity above a certain standard deviation of the mean indicate areas of the organ having increased activity and wherein voxels representing activity below a certain standard deviation of the mean indicate areas of the organ having reduced activity; and d) outputting by the one or more computers to an output device a representation of the organ showing areas of the organ having increased activity and/or reduced activity.
  • In exemplary embodiments, the invention further provides systems for assessing the activity of an organ in a subject comprising: a) an imaging system comprising: i) an imaging device for generating a quantitative three-dimensional image of the organ that is represented as voxels, wherein each voxel contains information about the activity of a portion of the organ; and ii) a computing device operatively connected to the imaging device and to a first display device; and b) one or more computers operatively connected to the imaging system, comprising one or more processors, a memory unit, and a computer-readable storage medium including computer-readable code that is read by the one or more processors to perform a method comprising the steps of: i) receiving by the one or more computers the generated three-dimensional organ image; ii) calculating by the one or more computers a mean of the activity represented by the voxels, wherein voxels representing values at upper and lower extremes are excluded from calculation of the mean; iii) calculating by the one or more computers a standard deviation of the mean obtained in step ii), wherein voxels representing activity above a certain standard deviation of the mean indicate areas of the organ having increased activity and wherein voxels representing activity below a certain standard deviation of the mean indicate areas of the organ having reduced activity; and iv) generating by the one or more computers a representation of the organ showing areas of the organ having increased activity and/or reduced activity.
  • In exemplary embodiments, the invention still further provides systems for assessing the activity of an organ in a subject comprising: a) one or more computing devices comprising one or more processors, a memory unit, and a computer-readable storage medium including computer-readable code that is read by the one or more processors to perform a method comprising the steps of: i) obtaining by the one or more computing devices a quantitative three-dimensional image of the organ that is represented as voxels, wherein each voxel contains information about the activity of a portion of the organ generated by an imaging device; ii) transmitting the generated three-dimensional organ image to one or more analysis computing devices; iii) obtaining a representation of the organ from the one or more analysis computing devices, wherein the representation shows areas of the organ having increased activity and/or reduced activity; and iv) displaying the obtained representation on the display device.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • The features and advantages of the disclosure can be more fully understood with reference to the following description of the disclosure when taken in conjunction with the accompanying figures, wherein:
  • FIG. 1 is a flow chart illustrating an exemplary method for identifying voxels having inactivity and/or compensatory activity in comparison to a baseline of the normal portions of the entire brain according to an exemplary embodiment of the present disclosure.
  • FIG. 2 is a schematic representation illustrating a imaging system operatively connected to one or more computing devices according to an exemplary embodiment of the present disclosure.
  • FIG. 3 is a flow chart illustrating an exemplary method for assessing the activity of an organ in a subject according to an exemplary embodiment of the present disclosure.
  • FIGS. 4A-4D are exemplary charts showing results of various psychometrics tests performed with a subject over a one year period.
  • FIG. 5A-5B show comparative quantitative PET images showing significant improvement in Case Study #1 from May 2011 (A) to February 2012 (B) consistent with improved cognitive scores.
  • DETAILED DESCRIPTION
  • In exemplary embodiments, the invention may provide a method for assessing the activity of an organ in a subject with the aid of a digital computer comprising:
  • a) accessing by one or more computers a quantitative three-dimensional image of the organ that is represented as voxels, wherein each voxel contains information about the activity of a portion of the organ;
  • b) calculating by the one or more computers a mean of the activity represented by the voxels, wherein voxels representing values at upper and lower extremes are excluded from calculation of the mean;
  • c) calculating by the one or more computers a standard deviation of the mean obtained in step b), wherein voxels representing activity above a certain standard deviation of the mean indicate areas of the organ having increased activity and wherein voxels representing activity below a certain standard deviation of the mean indicate areas of the organ having reduced activity; and
  • d) outputting by the one or more computers to an output device a representation of the organ showing areas of the organ having increased activity and/or reduced activity.
  • In exemplary embodiments, the method may comprise outputting by the one or more computers to the output device a representation of the organ showing areas of the organ having neither increased activity and/or reduced activity.
  • In exemplary embodiments, the invention may provide a system for assessing the activity of an organ in a subject comprising one or more processors, a memory unit, and a computer-readable storage medium including computer-readable code that is read by the one or more processors to perform a method comprising the steps of:
  • a) accessing by one or more computers a quantitative three-dimensional image of the organ that is represented as voxels, wherein each voxel contains information about the activity of a portion of the organ;
  • b) calculating by the one or more computers a mean of the activity represented by the voxels, wherein voxels representing values at upper and lower extremes are excluded from calculation of the mean;
  • c) calculating by the one or more computers a standard deviation of the mean obtained in step b), wherein voxels representing activity above a certain standard deviation of the mean indicate areas of the organ having increased activity and wherein voxels representing activity below a certain standard deviation of the mean indicate areas of the organ having reduced activity; and
  • d) outputting by the one or more computers to an output device a representation of the organ showing areas of the organ having increased activity and/or reduced activity.
  • In exemplary embodiments, the system may comprise outputting by the one or more computers to the output device a representation of the organ showing areas of the organ having neither increased activity and/or reduced activity.
  • Various values can be selected for use in excluding voxels representing values at upper and lower extremes from the calculation of the mean. As non-limiting examples, voxels can be excluded from calculation of the mean if the voxels represent values at the upper and lower 1%, 5% or 10% of the values.
  • In exemplary embodiments, other methods of excluding vowels that represent outlier values may be used. As one example, a first mean can be calculated of the activity represented by all the voxels. Then, voxels representing values at the upper and lower values can be excluded, either if the values are above or below a certain percentage of all values or if the values are above or below a certain standard deviation of the first mean. The voxels that are not excluded are then used to calculate a new mean of normal voxels.
  • Another method of excluding vowels that represent outlier values is to construct a histogram of values represented by all voxels, then fitting a curve to the histogram, and excluding voxels that deviate above or below the curve. These procedures can be performed by the one or more computers that calculated a mean of the activity represented by the voxels where voxels representing values at upper and lower extremes are excluded from calculation of the mean.
  • Standard deviation (SD) of the mean can be expressed, for example in 1SD, 0.1 SD or 0.01 SD units. For example, SD can be calculated in 0.01 or 0.1 SD units between 3.0, 3.5, 4.0 or 4.5 SD units below the mean to 3.0, 3.5, 4.0 or 4.5 SD units above the mean. As a further example, in one embodiment, standard deviation (SD) is calculated in 0.1 SD units between 4.0 SD units below the mean to 4.0 SD units above the mean.
  • In exemplary embodiments, different thresholds can be established for classifying voxels as representing increased activity or decreased activity. For example, a threshold can be set at 1.0 SD, 1.5 SD, 1.65 SD, 2.0 SD, 2.5 SD, 3.0, 3.5, 4.0 or 4.5 SD units above or below the mean. As a further example, in one embodiment, voxels representing activity above 1.5 SD units above the mean indicate areas of the organ having increased activity and voxels representing activity below 1.5 SD units below the mean indicate areas of the organ having reduced activity. Other variations can be used consistent with the letter and spirit of the present disclosure.
  • The organ from which the image is obtained can be, for example, brain, heart, lung, kidney, liver, pancreas, bladder, salivary glands, esophagus, stomach, gallbladder, intestines, colon, rectum, thyroid, parathyroid, adrenal gland, ureter, bladder, urethra, tonsils, adenoids, thymus, spleen, ovary, fallopian tube, uterus, vagina, mammary gland, testes, vas deferens, seminal vesicle, prostate, penis, pharynx, larynx, trachea, bronchi or lung, to name a few.
  • In exemplary embodiments, voxels from the one side of an organ can be compared with corresponding voxels from an opposite side of the same organ. For organs that occur on both sides of the body, such as for example, brain, lung or kidney, in exemplary embodiments, voxels from an organ on one side of the body can be compared with corresponding voxels from the corresponding organ on the opposite side of the body.
  • In exemplary embodiments, the image of the organ can be obtained using, for example, positron emission tomography (PET), functional magnetic resonance imaging (fMRI), any type or sequence of magnetic resonance imaging (MRI) including diffusion tensor magnetic resonance imaging, single photon emission computed tomography (SPECT), magnetic source imaging or optical imaging, to name a few. For example, three dimensional imaging of the organ can be obtained using positron emission tomography (PET) in connection with a computed tomography (CT) X-ray scan, or may be obtained using positron emission tomography (PET) in connection with any magnetic resonance scan.
  • Dedicated brain-only solid-state PET scanners are being developed by Hitachi. Such units may provide essential physiological information for a much lower patient radiation dose than existing PET CT machines. A PET CT general-purpose machine may generate a CT dose 10 times the radiation dose from a 15 milicurie FDG injection. The dedicated machine entirely does away with the CT dose and drops the required FDG dose by factor of five to about 3 mCi. In exemplary embodiments, such dedicated machines and the like can be used.
  • In exemplary embodiments, areas of increased or reduced activity in an organ can indicate a disease, an injury, a response to an injury, or functional changes in areas that have been disconnected from the remainder of the brain or spinal cord because of injury to connective structures. Non-limiting examples of such diseases or injuries include a tumor, stroke, infection, demyelinating disease, degenerative disease, dementia, ischemia, traumatic injury, shock wave injury, or primary or metastatic cancer, to name a few. For example, if the organ is the brain, areas of reduced activity can represent diffuse axonal injury, and/or represent areas of the brain disconnected from their source of workload. Functional connectivity MRI can be used to show which parts of the brain are communicating.
  • In exemplary embodiments, areas of disease or injury can be further analyzed by determining a ratio of a number of voxels showing increased activity to a number of voxels showing decreased activity within the area of disease or injury. Further analysis can include determining a ratio of a number of voxels showing increased activity to a number of voxels showing decreased activity within the entirety of a diseased area and/or at a border region between an area of disease or injury and normal tissue.
  • In exemplary embodiments, an image of the organ can be obtained and analyzed at a plurality of time points. Images obtained at different time points can be used, for example, to evaluate effectiveness of a course of treatment of a subject or to evaluate progression of disease.
  • For example, an image of the brain can be obtained and analyzed at a plurality of time points during neurological surgery or during neurological intensive care. Frequent serial brain PET studies can be used to guide neurological surgery and neurological intensive care of brain injured patients. In exemplary embodiments, periodic, or non-periodic repeated assessments may provide a tool for demonstrating response to therapy in a timely manner. By way of non-limiting example, studies may be repeated, e.g., a minimal interval of about three hours to a more common interval of daily, weekly, monthly, to name a few, to document brain glucose metabolism, brain oxygen metabolism, brain blood flow, and other vital parameters, to name a few. Some neurological surgery procedures have operating room durations in excess of 10 hours. Neurological intensive care can last for months.
  • As another example, an image of the heart can be obtained and analyzed at a plurality of time points during cardiac surgery, during cardiac interventional procedures, and/or during cardiac intensive care. In exemplary embodiments, frequent serial heart PET studies can be used to guide cardiac surgery and cardiac interventional intensive care of heart injured patients. Periodic and/or non-periodic repeated assessments may provide a tool for demonstrating response to therapy in a timely manner. Studies may be repeated, e.g., a minimal interval of about 5 minutes to a more common interval of daily, weekly, monthly, to name a few, to document cardiac nutritional blood flow using rubidium 82, cardiac FDG metabolism using fluorine 18; cardiac oxygen metabolism using oxygen 15, and other vital parameters, to name a few.
  • Voxels within an area of disease or injury in the organ can be analyzed at a plurality of time points, and a ratio of a number of voxels within the area showing increased activity over time to a number of voxels within the area showing decreased activity over time can be used as a measure of whether the disease or injury is improving or not improving. For example, if the disease is cancer, a decrease in the ratio of the number of voxels within the area of disease showing increased activity over time to the number of voxels within the area of disease showing decreased activity over time is indicative of a favorable outcome. As another example, if the disease is reduced blood flow to the area, an increase in the ratio of the number of voxels within the area showing increased activity over time to the number of voxels within the area showing decreased activity over time is indicative of a favorable outcome.
  • In exemplary embodiments, the subject can be any living organism, including any type of animals, such as humans.
  • The methods disclosed herein can comprise imaging the subject to obtain an image of the organ.
  • In exemplary embodiments, a system for assessing the activity of an organ in a subject may comprise:
  • a) an imaging system comprising:
  • i) an imaging device for generating a quantitative three-dimensional image of the organ that is represented as voxels, wherein each voxel contains information about the activity of a portion of the organ; and
  • ii) a computing device operatively connected to the imaging device and to a first display device; and
  • b) one or more computers operatively connected to the imaging system, comprising one or more processors, a memory unit, and a computer-readable storage medium including computer-readable code that is read by the one or more processors to perform a method comprising the steps of:
  • i) receiving by the one or more computers the generated three-dimensional organ image;
  • ii) calculating by the one or more computers a mean of the activity represented by the voxels, wherein voxels representing values at upper and lower extremes are excluded from calculation of the mean;
  • iii) calculating by the one or more computers a standard deviation of the mean obtained in step ii), wherein voxels representing activity above a certain standard deviation of the mean indicate areas of the organ having increased activity and wherein voxels representing activity below a certain standard deviation of the mean indicate areas of the organ having reduced activity; and
  • iv) generating by the one or more computers a representation of the organ showing areas of the organ having increased activity and/or reduced activity.
  • In exemplary embodiments, the method performed by the one or more processors can comprise displaying by the one or more computers the generated representation of the organ on a second display device operatively connected to the one or more computers. The method performed by the one or more processors can also comprise transmitting from the one or more computers the generated representation of the organ to the imaging system so as to be displayed on the first display device.
  • In exemplary embodiments, the image of the organ can obtained using, e.g., positron emission tomography (PET), functional magnetic resonance imaging (fMRI), any type or sequence of magnetic resonance imaging including diffusion tensor imaging (MRI); magnetic source imaging, optical imaging, computed tomography (CT) X-ray scan, or combinations thereof, to name a few. In some exemplary embodiments, the image of the organ may be obtained using positron emission tomography (PET), alone, or in combination with CT or MRI.
  • In exemplary embodiments, a system for assessing the activity of an organ in a subject comprising one or more computing devices may comprise one or more processors, a memory unit, and a computer-readable storage medium including computer-readable code that is read by the one or more processors to perform a method comprising the steps of:
  • i) obtaining by the one or more computing devices a quantitative three-dimensional image of the organ that is represented as voxels, wherein each voxel contains information about the activity of a portion of the organ generated by an imaging device;
  • ii) transmitting the generated three-dimensional organ image to one or more analysis computing devices; iii) obtaining a representation of the organ from the one or more analysis computing devices, wherein the representation shows areas of the organ having increased activity and/or reduced activity; and
  • iv) displaying the obtained representation on the display device.
  • In exemplary embodiments, the representation of the organ can be generated using the transmitted three-dimensional organ image at the one or more analysis computers by a method comprising, e.g., the steps of:
  • i) calculating a mean of the activity represented by the voxels of the three-dimensional organ image, wherein voxels representing values at upper and lower extremes are excluded from calculation of the mean; and
  • ii) calculating a standard deviation of the mean obtained in step i), wherein voxels representing activity above a certain standard deviation of the mean indicate areas of the organ having increased activity and wherein voxels representing activity below a certain standard deviation of the mean indicate areas of the organ having reduced activity.
  • In exemplary embodiments, a voxel analysis of the patient's own organ can be used to establish mean voxel values. Median and mode voxel values can also be determined. The fundamental principles of voxel-based morphometric (VBM) methods are well known.
  • In exemplary embodiments, a histogram may be provided, ranging from −4 standard deviations to +4 standard deviations, for example, in 0.1 standard deviation steps illustrating the distribution of voxels within the boundaries of the organ being examined. This histogram display of voxels can be used to select those voxels which will be statistically analyzed and graphically displayed. In a normal organ one expects a Gaussian distribution of voxels.
  • In exemplary embodiments, voxels can be analyzed using, for example, commercially available software such as provided by MIM Software Inc. (Cleveland, Ohio).
  • In exemplary embodiments, volumetric three-dimensional outlines of clusters can be viewed in a cinematic mode, for example, proceeding from −4 standard deviations toward −1 standard deviation thereby showing areas of each degree of damage. Similarly a cinematic review of +3 standard deviation volumetric three-dimensional outlines allows demonstration of compensatory increase in neuronal function of undamaged structures and other recruited pathways. Such analysis can further verify the reality of damaged tissue by demonstrating the reality of compensatory mechanisms.
  • Where clusters of inactivity or compensatory activity are found, in exemplary embodiments, different indicia such as color overlays, text labels, boundary outlines or the like may be applied to the visual display output. The display output can be a computer monitor but may also be high resolution printers as well, or other display devices. Three-dimensional volumetric displays of medical data are becoming increasingly available.
  • According to an exemplary embodiment, the invention may include the ability to generate a short, cycling presentation of the identified voxels (inactive and/or compensatory) at a plurality of standard deviations. This cycling presentation or animation may be presented in three-dimensional contours of the organ. Three-dimensional contours of details of degree of metabolism within areas of damage can be simultaneously displayed.
  • In exemplary embodiments, the number of voxels within the three-dimensional boundaries defined by standard deviations, such as, for example, 3, 2.5, 2.0, 1.5, and 1.0 standard deviations above or below the mean of non-involved tissue within that patients organ can be mapped over time to provide a very sensitive analysis of response to therapy versus progression of disease.
  • In an exemplary embodiment, the brain quantitative analysis program may automatically cycle from the lowest transaxial slice to the highest transaxial slice. In some exemplary embodiments, the thickness of the slice can be adjusted from 4 mm to 20 mm.
  • Exemplary embodiments of the present disclosure may be applicable to a large range of noninvasive imaging modalities that can be used to address and quantitate changes in tissue physiology repair and disease processes over time.
  • In exemplary embodiments, clusters of voxels may be defined by deviants from the mean and can clearly show both the epicenter, the umbra and the penumbra of any imaginable physiological deviance within any organ, and may be measured by any modality that is voxel-based. For example, imaging MRI, functional MRI, diffusion tensor MRI, and other experimental MRI sequences may be candidates for such analysis. In exemplary embodiments, such modalities may include positron emission tomography, magnetic resonance imaging, single photon emission computed tomography, CT, volumetric ultrasound, optical tissue imaging, and all other means of noninvasive volumetric imaging of living tissues.
  • In exemplary embodiments, symmetrical organs such as brain and kidneys, comparison can be made with the corresponding area in the contralateral side, bearing in mind that within the brain, the contralateral structure may be up-regulated to compensate for decreased function in the injured structure.
  • In exemplary embodiments, diffuse axonal injuries in the brain may generally appear as scattered small areas of decreased glucose metabolism on the gyri of the cerebral cortex. These lesions may be almost impossible to visually identify because of their location on a variable terrain. In some exemplary embodiments, voxel-based threshold imaging may clearly identify small scattered lesions.
  • In exemplary embodiments, objective quantification of the number, size, severity, and location of, for example, areas of decreased glucose metabolism within the brain may be possible without the need of a control group. Thus, possible artifacts generated by arbitrary brain deformation may be avoided. In some exemplary embodiments, serial quantification of number, size, severity and location of injured areas may provide objective documentation of quantitative response to therapy. For example, therapies such as drug intervention and rehabilitation intervention can be compared with the spontaneous natural history of the untreated pathological process.
  • Within the brain, amyloid protein is commonly deposited at areas of injury, potentially leading to progressively greater injury over time due to amyloid toxicity. In exemplary embodiments, amyloid brain imaging may be a natural adjunct to fluorine 18 deoxyglucose brain imaging in traumatic brain injury.
  • There may be multiple patterns of injury following trauma to the brain including coup-contrecoup contusion of brain surfaces, axonal damage by propagation of shear forces resulting in Wallerian degeneration and death of widely distributed neurons whose axons assembled into a tract within the path of shear forces.
  • In exemplary embodiments, baseline measurements may be made on individuals involved in contact sports who can be tracked season by season. In exemplary embodiments, the present invention can be used to identify the vulnerable post-concussion time during which repeated trauma can produce disproportionate severe damage.
  • Military personnel can be screened for susceptibility to additional blast injury predeployment, potentially decreasing the total number of individuals whose cumulative brain damage renders them nonfunctional. Most individuals have a degree of cognitive reserve which masks the behavioral and neurological signs and symptoms of lesser degrees of brain injury.
  • According to exemplary embodiments, in any area of diseased tissue, adjacent voxels may include volumes of cells with improving metabolism adjacent to volumes of cells with declining metabolism. In some exemplary embodiments, the ratio of voxels advancing to voxels declining may be a measure of whether the overall physiology is favoring regeneration or death. In some exemplary embodiments, whether the process is cancer where one wants the decline to be predominant or areas of blocked blood flow where one wants the advance to be predominant, progress of the local physiological condition can be objectively measured in a timely fashion to allow therapeutic intervention with near real-time monitoring of the results. This may allow one to measure the status of the region, intervene therapeutically, and then remeasure.
  • In exemplary embodiments, each patient, and each area of brain hypometabolism may require frequent monitoring to detect the local advance decline ratio. For example, each patient and each area of brain hypometabolism may have differing dose response curves for any therapeutic intervention.
  • In exemplary embodiments, the ratio of the number of voxels improving/number of voxels worsening in an anatomical area can provide a unique measure of overall disease progression and treatment effectiveness over time. In addition to the injured or diseased area itself, the border between normal and abnormal tissue areas may be another region of interest.
  • In exemplary embodiments, the number of voxels in each degree of deviance from the mean may be obtained, and serial images may be displayed, such as, for example, starting with those voxels that are most negative (−4 standard deviations). Further, the obtained voxels may be summed with all interval voxels to a selected endpoint, such as, for example, −1.65 standard deviations. This may produce a quantitative three-dimensional volumetric map of the range of disease. This map may be electronically saved on any suitable computer-readable storage device and subsequently used to quantitatively compare with a second volumetric map obtained after therapy in accordance with the expected time course of disease resolution. For example, the second map may be obtained one to three months after therapy relating to chronic conditions. In other situations, the second map may be obtained one to three days after therapy relating to acute conditions.
  • In exemplary embodiments, the quantitative disease assessment taking place at regular intervals may serve as an objective measurement of the efficacy of any drug or interventional therapy. For example, in a laboratory or a clinical research setting more frequent observations can document the physiology of the repair sequence. Thus surrogate markers for pharmacological intervention trials may be validated. These can be of immense help in drug discovery. These can also be of immense help in determining whether an individual patient is benefiting from the intervention. Non-responders can be spared potential toxicity that is not offset by benefit.
  • In some exemplary embodiments, a histogram display of all of the voxels within the defined boundaries of a disease process within a specific anatomical area may be provided. For example, an area of traumatic brain injury in the right frontal lobe may contain 500,000 voxels. 100,000 of these voxels may be located within plus and minus 1 millimeter of the transition zone from affected tissue to normal tissue, the apparent visual boundary of the disease process. The 100,000 voxels in the transition zone will be expected to display a wide range of metabolic uptake values. The voxels which are more centrally located will also be expected to exhibit a wide range of metabolic uptake values. All of the voxels within the visual boundary of the disease process are likely to change metabolic uptake over time as the cells improve or die.
  • In an exemplary embodiment, a software product may be used for detecting diffuse axonal injuries in a brain. The software product may be any suitable computer-readable storage media that contains instructions, that when executed, cause one or more computers to perform the steps: accessing a digital brain scan of a subject's entire brain; quantitatively identifying voxels having inactivity of, e.g., −1.65 standard deviations or less from that of the entire brain, or activity of, e.g. +1.65 standard deviations or more; establishing a threshold value for localizing one or more clusters of said identified voxels; applying a clustering algorithm to localize said one or more clusters; generating a revised digital brain scan image with visually perceptible indicia associated with said one or more clusters localized; and displaying said revised digital brain scan image on an output device.
  • FIG. 1 shows, according to an exemplary embodiment, a method for detecting diffuse axonal injuries. At step 105, a volumetric digital brain scan image of a subject's entire brain may be obtained or accessed. At step 110, voxels may be quantitatively identified which are, e.g., −1.5 standard deviations or less from that of the entire brain which may indicate inactivity and/or are, e.g., +1.5 standard deviations or more from the entire brain which may indicate compensatory activity. At step 115, one or more threshold values may be established for localizing one or more clusters of said identified voxels. At step 120, a clustering algorithm may be applied to localize said one or more clusters using the one or more threshold values. For example, the clustering algorithm may be applied to the identified voxels above or below the 1.5 standard deviations from the brain. At step 125, one or more indicias may be generated with respect to the one or more sets of identified clusters. Using the generated indicias, at step 130, a revised digital brain scan image with visually perceptible indicia associated may be generated. At step 135, a revised digital brain scan image may be displayed on an output device. At step 140, based on the generated image, alternative pathways to and from the areas of identified areas of compensatory activity may be stimulated.
  • In some exemplary embodiments, the method as illustrated in FIG. 1 may further comprise the steps of: accessing a digital brain scan image of a subject's entire brain; quantitatively identifying voxels having inactivity of at a plurality of standard deviations less than, e.g., −1.0; establishing a threshold value for localizing one or more clusters of said identified voxels; applying a clustering algorithm to localize said one or more clusters; sequentially generating a plurality of revised digital brain scan images with visually perceptible indicia associated with said one or more clusters localized at each standard deviation value; and displaying said revised digital brain scan image on an output device.
  • According to an exemplary embodiment, diffuse axonal injuries may be detected in a brain by implementing a method comprising the steps of: accessing a digital brain scan image of a subject's entire brain; quantitatively identifying voxels having compensatory activity of at a plurality of standard deviations greater than, e.g., 1.0; establishing a threshold value for localizing one or more clusters of said identified voxels; applying a clustering algorithm to localize said one or more clusters; sequentially generating a plurality of revised digital brain scan images with visually perceptible indicia associated with said one or more clusters localized at each standard deviation value; and displaying said revised digital brain scan images on an output device. In some exemplary embodiments, the revised digital brain scan images may be presented in three-dimensional contours.
  • According to another exemplary embodiment, FIG. 2 shows an imaging system, generally designated by number 5. The imaging system 5 may include one or more imaging devices designated by number 10, that may be operatively connected to one or more computing devices generally designated by number 20. The imaging device 10 may generate an quantitative three-dimensional image of an organ, such as, for example, a brain, heart, lung, kidney, liver, pancreas, bladder, salivary glands, esophagus, stomach, gallbladder, intestines, colon, rectum, thyroid, parathyroid, adrenal gland, ureter, bladder, urethra, tonsils, adenoids, thymus, spleen, ovary, fallopian tube, uterus, vagina, mammary gland, testes, vas deferens, seminal vesicle, prostate, penis, pharynx, larynx, trachea, bronchi and lung, to name a few. In exemplary embodiments, the image of the organ may be generated using positron emission tomography (PET), computed tomography (CT) X-ray scan, functional magnetic resonance imaging (fMRI), magnetic source imaging or optical imaging, or combinations thereof. For example, the three-dimensional imaging maybe obtained using a PET scan in connection with a CT X-ray scan.
  • In exemplary embodiments, the imaging system 10, and by extension, any one of its components, may be operatively connected to one or more computer networks 50, such as, for example, the Internet, or any other suitable network, via, by way of example, a set of routers and/or networking switches. The imaging system 10 may be connected to an imaging analysis system 30 or any one of its components. For example, the imaging analysis system 30 may include one or more analysis computers, designated by number 40. The analysis computers 40 may include one or more processors, computer readable storage media, and memory units. The one or more processors may read and execute software embodied as instructions stored on the computer readable storage media, according to exemplary embodiments herein.
  • In exemplary embodiments, the analysis system 30 may be used to assess the activity of organ. Referring to FIG. 2, at step 205, the analysis computers 40 may obtain a image scan of an organ. The organ may be from an animal, including a human. The image scan data generated by the imaging device 10 may be sent directly or indirectly to the analysis system 30.
  • The obtained image scan may be a quantitative three-dimensional image of the organ. This image or image scan may include voxels or voxel data, wherein each voxel contains information about the activity of a portion of the imaged organ. In one exemplary embodiment, the imaging device 10 may generate a PET scan of the organ in a Digital Imaging and Communications in Medicine (DICOM) format. In this regard, the image or scan data may contain at least four elements as follows: an x coordinate, a y coordinate, a z coordinate, and a value measured at the x, y, and z coordinates. Since DICOM is a standard covering both data formats and protocols for communications, the image scan/data may be obtained several ways. See DICOM at: http://en.wikipedia.org/wiki/DICOM.
  • At step 210, the obtained image scan may be used by the analysis computers 40 to calculate activity using the voxels. For example, the mean of the activity represented by the voxels may be calculated. In some exemplary embodiments, voxels representing extreme upper and lower values may be excluded. Voxels representing values at the upper and/or lower 1%, 5%, 10%, or any other appropriate voxels representing values in an extreme range may be excluded.
  • At step 215, the analysis computers 40 may further, based on the calculated mean, calculate one or more voxel threshold values. In an exemplary embodiment, the analysis computers 40 may calculate a standard deviation using the calculated mean. For example, the standard deviation may be calculated in 0.1 standard deviation (SD) units between 4.0 SD units below the mean to 4.0 SD units above the mean. In some exemplary embodiments, the standard deviation may be calculated in 0.01 standard deviation (SD) units. In some embodiments, the standard deviation may be calculated in units between 3.0 SD units below the mean to 3.0 SD units above the mean.
  • At step 220, the analysis computers may determine voxels are outside or beyond the calculated threshold values. The analysis computers 40 may determine voxels which are a specified standard deviation above or below the mean, as such voxels may respectively indicate areas of the organ with increased or decreased activity. For example, voxels representing activity 1.65 SD units above or below the mean may indicate, respectively, increased or decreased activity. In some exemplary embodiments, other standard deviation unit values may be used to indicate activity/inactivity. For example, voxels representing activity anywhere from 1.00-4.00 SD units above or below the mean may indicate increased or decreased activity.
  • At step, 225, the calculated data regarding the voxels may be stored, such as in databases 35, for future use. At step 230, a representation of the organ, based on the calculations performed by the analysis computers 40, may be outputted to an output device to show the areas of the organ with increased and/or decreased activity. For example, the analysis computers 40 may be connected to a display device to display the representation of the organ. In some exemplary embodiments, the displayed representation may be a histogram.
  • In some exemplary embodiments, software such as the MIMneuro may be used at least by the analysis computers 40 to perform one or more of the calculations and generate a representative output based on such calculations, such as for example a histogram.
  • In some exemplary embodiments, the representation of the output representation of the organ showing increased/decreased activity may be sent from the analysis computers 40 to the imaging system 10. For example, the output representation may be displayed a on a display operatively connected to the computer 20. The imaging device 10 and/or computer may be located any suitable locations, such as, for example, a doctor's office, a hospital, a clinic, to name a few.
  • The output representation and associated calculations related to the organ may be used by a physician. In an exemplary embodiment, a physician may observe a representation, such as histogram of the organ scan. For example, the physician may select a range of histogram bars representing voxel values that are a certain amount of standard deviations away from the mean for the entire organ scan, such as for example, 1.5 SD units, 1.65 units, to an name a few. In this regard, such a selection may be symmetrical about the mean. For instance, if a large count of voxels (i.e. a spike) occurs at −1.3 standard deviations, then something less than 1.3 standard deviations will be selected as the “normal range” both above the mean and below the mean, and equidistant from the mean. Further, the physician may perform a visual verification of the normal area. Further, the analysis computers 40 or computer 20 may be used to display a visual map of the scan data that highlights the “normal area” as a result the physician's selection. If the selection verifies, then the mean, median and mode may be calculated and stored for future comparisons.
  • In exemplary embodiments, areas of increased or reduced activity in the organ indicate a disease or an injury, such as, for example, a tumor, stroke, infection, demyelinating disease, degenerative disease, dementia, ischemia, traumatic injury, or primary or metastatic cancer, to name a few. For example, with respect to the brain, areas of reduced activity in the organ may represent diffuse axonal injury.
  • Further processing regarding the voxels may include rescaling the voxels and calculating an advance/decline ratio. The voxels may be rescaled so as to eliminate any biases, with any scaled data and/or scaling factors may be stored for future reference. The advanced/decline ratio may also be stored for future reference. In addition, depending on the type of organ imaged, the voxels from one side of the imaged organ may be compared with the corresponding voxels on the opposite side of the same organ. Similarly, voxels from one organ on side of the body may be compared with corresponding voxels on the corresponding organ on the opposite side of the body.
  • Analyses preformed using the voxels may include determining a ratio of a number of voxels showing increased activity to a number of voxels showing decreased activity at a border region between an area of disease or injury and normal tissue.
  • The process of accessing organ activity as illustrated in FIG. 2 may be repeated over a period of time at certain intervals so as to determine any changes in activity. In this regard, an image of the organ may obtained and analyzed at a plurality of time points. The images obtained at different time points may be used to evaluate effectiveness of a course of treatment of a subject or to evaluate progression of disease. The voxels within an area of disease or injury in the organ may be analyzed at a plurality of time points and a ratio of a number of voxels within the area showing increased activity over time to a number of voxels within the area showing decreased activity over time may be a measure of whether the disease or injury is improving or not improving.
  • In the case of a human brain being imaged/scanned, psychometric tests may be used in addition or in conjunction with to assess and/evaluate the brain and its activity.
  • In situations where a brain is being analyzed or accessed, a plurality of psychometric tests may also be administered with respect to the patient over the same period of time. In any event, after the process is repeated various things may be tracked, such as for example, the absolute number of voxels, the advanced/decline ratio, and the percentage of activity change in certain areas, to name a few. FIGS. 4A-4B, shows results of various psychometric tests that may administered over a 1 year time period.
  • It will be seen that the advantages set forth above, and those made apparent from the foregoing description, are efficiently attained and since certain changes may be made in the above construction without departing from the scope of the invention, it is intended that all matters contained in the foregoing description or shown in the accompanying drawings shall be interpreted as illustrative and not in a limiting sense. This invention will be better understood from the Experimental Details, which follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully in the claims that follow thereafter.
  • EXPERIMENTAL DETAILS Case Study #1 Quantitative Evaluation Post Hyperbaric Oxygen Therapy
  • History:
  • RM, a 46 year old male suffered traumatic brain injury when he fell on his head from a loft, a distance of 8 feet in February 1997. The patient was severely incapacitated, declared totally and permanently disabled by Social Security and was evaluated at Mayo Clinic Jacksonville. With remarkable persistence in a self-directed rehabilitation program, he was able to resume gainful employment after several years. Subsequently, the patient reported hitting his head from a major bicycle accident and hitting his head when he walked into an obstruction at a warehouse. Patient self-referred in May 2011 with complaints of anxiety, depression, intermittent dissociation, decreased ability to concentrate, and memory loss. At the time of referral, the patient had been self-medicating with alcohol and had stopped self-directed rehabilitation.
  • Care Plan:
  • The patient was advised to abstain from self-medicating with alcohol. Rx 50 mg Trazadone at night. Self-directed 45 hours of 1.3 atmospheric pressure 90% oxygen.
  • PET Studies:
  • Upon referral (May 3, 2011) patient received a Quantitative PET brain study and underwent multiple cognitive and self-reporting psychometric testing during the following 12 month period. On Aug. 18, 2011 (75 days later) the patient received a second Quantitative PET brain study and continued cognitive and psychometric testing. The PET studies were analyzed using a custom neurological software package.
  • Referring to FIGS. 5A and 5B, Comparative Quantitative Imaging showed significant improvement from May 2011 to February 2012 consistent with improved Cognitive scores (Table 1). Significant improvement is noted especially in frontal lobes. Referring to FIG. 5A, the patient's brain is imaged showing areas 501, 502, 503, 504, and 505 with decreased activity. FIG. 5B shows the imaged brain in February 2012, with improvement in those same areas.
  • RM has had about seventy 1.3 atmosphere hyperbaric treatments since November, 2011. Patient reports mediation 3 to 5 times a week, no drinking, and consistent vitamin B complex use since Nov. 26, 2011. His family and economic stress level are twice as high as compared to a year ago. RM has shown remarkable improvement in frontal lobe PET scan hypometabolism, remarkable improvement in Processing Speed, and significant improvement in Neurocognitive Index.
  • TABLE 1
    A. Cognitive changes over time for Case Study #1
    03- 12- 17- 21- 10- 15- 17- 25- 30- 09- 24-
    May Jul Jul Jul Aug Aug Aug Aug Aug Nov Jan
    NC 63 68 66 73 81 87 82 93 90 77 70
    index
    Comp 21 40 63 30 45 75 50 90 34 61 55
    M
    Verbal 12 30 58 63 12 55 63 79 30 37 63
    M
    Visual 45 53 66 13 81 81 37 90 45 75 45
    M
    Psych 86 84 34 96 96 96 98 96 99 94 90
    motor
    speed
    RT 42 45 70 58 93 95 86 86 93 66 32
    CA 82 82 63 63 58 58 58 70 77 77 82
    CF 70 81 87 90 86 90 96 96 97 78 82
    Proc 5 5 13 40 18 34 27 75 53 18 4
    speed
    Exec 68 84 86 95 88 93 98 96 97 81 81
    func
    Total 494 572 606 621 658 764 695 871 715 664 604
    B. Cognitive changes over time for Case Study #1 (Continuation of Table 1A)
    31- 04- 06- 04- 11- 21- 26- 18- 23- 02-
    Jan Feb Feb Mar Mar Mar Jan Apr Apr May
    NC 63 82 82 90 90 84 91 93 93 95 1713
    index
    Comp 12 70 40 79 70 61 82 70 61 61 1170
    M
    Verbal 16 79 30 90 90 73 63 63 73 63 1142
    M
    Visual 18 53 53 53 37 45 86 68 45 53 1142
    M
    Psych 95 99 99 99 99 99 99 99 99 99 1955
    motor
    speed
    RT 58 70 79 73 81 68 82 86 75 75 1513
    CA 77 70 82 82 82 70 77 70 82 82 1544
    CF 66 79 87 94 93 81 95 96 96 98 1838
    Proc 25 53 77 53 63 92 75 97 96 99 1022
    speed
    Exec 66 79 86 95 93 79 96 96 96 98 1851
    func
    Total 496 734 715 808 798 752 846 838 816 823
    NC index—Neuro-cognitive index, Comp M—Composite memory, Verbal M—Verbal memory, Visual M—Visual Memory, Psych motor speed—Psycho-motor speed, RT—Reaction time, CA—Complex attention, C—Cognitive flexibility, Proc speed—Processing speed, Exec func—Executive function
  • Case Study #2 NFL Player
  • Clinical Diagnosis:
  • Traumatic brain injury with persistent symptoms: severe headaches, memory loss requiring constant notations in a diary, difficulties with anger and rage, difficulty sleeping, sleepwalking, talking in his sleep, “terrible” “horrible” short-term memory, and perceptions of space closing in on him, especially in crowds.
  • He experiences significant visual impairment, as well as severe dizziness if he bends over after exercise. He finds a 45 minute trip on the interstate very difficult. He is chronically frustrated and upset. He is in marital counseling. He has just experienced the third anniversary of his second marriage. He has children by his first marriage ages 24 and 18. He divorced in 2008. He is currently unemployed; applying for social security disability.
  • Summary of Brain Surface Visual Findings:
  • Cortical confluent hypometabolic areas are seen at the base of the brain centering on the brainstem, pons, cerebellar vermis and cerebellar peduncles. The inferior aspects of cortical and subcortical regions of both temporal lobes are hypometabolic; the medial aspects of both cerebellar hemispheres are involved; there is also significant spotty cortical and subcortical hypometabolism of the inferior aspects of the frontal lobes. Midline images of the brain demonstrate severe extensive hypometabolism of the basal ganglia and midbrain.
  • Right Frontal Lobe:
  • There is a severely hypometabolic right frontal lobe area measuring 4.9 cm in height by 1.4 cm in width by 1.25 cm in anterior-posterior dimension involving most of the right superior frontal gyms. There is a large area of hypometabolism involving the right inferior frontal gyms pars triangularis measuring 2.5 cm in height by 1.4 cm in width by 1.9 cm in anterior-posterior dimension. The right frontal gyms is hypometabolic; right superior frontal gyrusis hypometabolic; right middle frontal gyms is hypometabolic; right orbitofrontal region including the medial orbital gyms is hypometabolic. Right supplementary motor area is extensively hypometabolic. Right precentral gyms contains a hypometabolic area measuring 2 cm in height by 1.8 cm in width. The right superiormedial frontal gyms is severely hypometabolic measuring 2.8 cm in length by1.5 cm in width.
  • Left Frontal Lobe:
  • There is a mirror image hypometabolic area measuring 2.3 cm in height by 0.7 cm in width involving much of the left superior frontal gyms. Hypometabolism is extensive in the left orbitofrontal region including the medial orbital gyms. The left anteriororbital gyms is hypometabolic. The right inferior medial frontal gyms is hypometabolic; left superior frontal gyms measuring 0.7 cm diameter is severely hypometabolic, left middle frontal gyms is hypometabolic. Left supplementary motor area is extensively hypometabolic. Left middle frontal gyms is hypometabolic. Left superior frontal gyms is hypometabolic; left precentral gyms is hypometabolic; left superior frontal gyms is hypometabolic. The left superior medial frontal gyms is severely hypometabolic measuring 2 cm in anterior-posterior dimension and about 1.5 cm in width.
  • Insula:
  • There is focal hypometabolism within the right insula.
  • Right Temporal Lobe:
  • Hypometabolism of the inferior aspects of the right temporal lobe extending into the medial area. The right fusiform gyms is extensively hypometabolic; right hippocampus is extensively hypometabolic measuring 2.9 cm in height by 1.3 cm in width by 4.4 cm in oblique anterior-posterior length. Right temporal pole is hypometabolic.
  • Left Temporal Lobe:
  • Hypometabolism of the inferior aspects of the left temporal lobe extending into the medial area as is the left fusiform gyms. The left temporal pole is hypometabolic; the left fusiform gyms is involved. The left hippocampus is significantly hypometabolic.
  • Right Parietal Lobe:
  • The right rolandic operculum is hypometabolic; The right super marginal gyms is hypometabolic. The right precentral gyms is hypometabolic. The right posterior cingulate gyms is hypometabolic. The right superior parietal lobule is extensively hypometabolic. The right precentral gyms is hypometabolic. The right superior parietal lobule is extensively and severely hypometabolic. The right angular gyms is hypometabolic as is the right supra-marginal gyms.
  • Left Parietal Lobe:
  • The left rolandic operculum is hypometabolic. The left super marginal gyms is hypometabolic; the left precentral gyms is hypometabolic; the left postcentral gyms is hypometabolic; left superiorparietal lobule is hypometabolic; the left pre-post central gyms is hypometabolic; the left superior parietal lobule is very extensively and severely hypometabolic. Left supra marginal gyms is hypometabolic. Left angular gyms is hypometabolic.
  • Basal Ganglia:
  • The putamen is hypometabolic bilaterally. The globis pallidus bilaterally is extensively hypometabolic.
  • Thalamus:
  • The right thalamus is severely hypometabolic measuring about 3 cm in height by 2.1 cm in anterior-posterior dimension. Left thalamus is severely hypometabolic measuring 4.2 cm in height by 2.2 cm in width.
  • Right Occipital Lobe:
  • The right superior occipital gyms shows extensive hypometabolism. There is definite involvement of the right primary visual cortex. The right lingual gyms inferior to the right primary visual cortex is also severely hypometabolic.
  • Left Occipital Lobe:
  • There is definite involvement of the left primary visual cortex measuring 2.3 cm in height by 1.3 cm in width, by 2.6 cm in anterior-posterior dimension. There is very extensive involvement of the left primary visual cortex. The left superior occipital gyms has extensive hypometabolism. Adjacent structures in the left occipital lobe are also hypometabolic. The left lingual gyms is hypometabolic and the right superior occipital gyms is hypometabolic; the right fusiform gyms is hypometabolic. The left fusiform gyms and left inferior occipital gyms are focally hypometabolic
  • Cerebellum:
  • There is extensive hypometabolism involving the right inferior and superior cerebellar peduncles. There is moderately extensive hypometabolism of the left inferior and superior cerebellar peduncles. The midline cerebellar vermis is extensively hypometabolic measuring 2.4 cm in width by 1.14 cm anterior-posterior.
  • Quantitative Findings:
  • Areas of the brain where the hypometabolism is so severe and extensive that the average metabolic rate of the entire structure is statistically depressed.
  • TABLE 2
    Areas of extensive hypometabolism in Case Study #2.
    Structure Midline Left Right
    base of po −2.4 SD
    globis pallidus −2.2 SD −2.2 SD
    superior cerebellar −0.9 SD −2.1 SD
    peduncle
    middle cerebellar −1.0 SD −1.5 SD
    peduncle
    inferior cerebellar −0.7 SD −1.8 SD
    peduncle
    brainstem −1.4 SD
    thalamus −1.3 SD −1.4 SD
    primary visual cortex −1.3 SD −1.2 SD
    lingual gyrus −1.0 SD −1.2 SD
    amygdala −1.2 SD −0.6 SD
  • Example
  • −2 SD means 97.5% of people function better.
  • TABLE 3
    Percentages of regions of brain showing hypometabolism.
    Max Min Volume %
    Contour (z-score) (z-score) (ml) Volume
    WHOLE BRAIN 4.21 −4.91 2417.8
    WHOLE BRAIN HYPO −1.65 −4.91 123.9 5.1%
    Frontal Lobe 4.21 −4.91 576.9
    Frontal Lobe Hypo −1.65 −4.91 32.1 5.6%
    Occipital Lobe 3.66 −3.94 225.7
    Occipital Lobe Hypo −1.65 −3.94 15.3 6.8%
    Parietal Lobe 3.71 −4.77 341.8
    Parietal Lobe Hypo −1.65 −4.77 23.7 6.9%
    Temporal Lobe 3.66 3.94 307.3
    Temporal Lobe Hypo −1.65 −3.94 9.8 3.2%
    Hypo: hypometabolism.
  • Impressions:
  • This patient demonstrates extensive severe traumatic brain injury in both the right and left sides of his brain. Very severe memory impairment is directly traceable to hypometabolism in both hippocampi, and bilaterally in the thalamus. Visual difficulties are directly traceable to bilateral hypometabolism in the primary visual cortex. Difficulties with emotional self-regulation are directly correlated with hypometabolism in both amygdala, as well as extensive areas of hypometabolism in the frontal cortex bilaterally.
  • REFERENCES
    • Ashburner J and Friston K J. Voxel-Based Morphometry—The Methods. NeuroImage 11: 805-821, 2000.
    • Garcia-Panach J., et al. A voxel-based analysis of FDG-PET in traumatic brain injury: regional metabolism and relationship between the thalamus and cortical areas. J Neurotrauma 28(9): 1707-17, 2011.
    • Kato T, et al. Statistical image analysis of cerebral glucose metabolism in patients with cognitive impairment following diffuse traumatic brain injury. J. Neurotrauma 24(6): 919-926, 2007.
    • Mummery C J, Patterson K, Price C J, Ashburner J, Frackowiak R S J, Hodges J R. A voxel-based morphometry study of semantic dementia: relationship between temporal lobe atrophy and semantic memory. Ann Neurol 47:36-45, 2000.
    • Kim I., et al. Age- and Sex-Associated Changes in Cerebral Glucose Metabolism in Normal Healthy Subjects Statistical Parametric Mapping Analysis of F-18 Fluorodeoxyglucose Brain Positron Emission Tomography. Acta Radiol: 50(10):1169-74, 2009.
    • Shiga T., et al. A new PET scanner with semiconductor detectors enables better identification of intratumoral inhomogeneity. Journal of Nuclear Medicine 50(1): 148-155, 2009.
    • Zhang J. et al. Statistical parametric mapping and cluster counting analysis of [18F] FDG-PET imaging in traumatic brain injury. J. Neurotrauma. 27(1): 35-49, 2010.

Claims (20)

1. A system for assessing the activity of an organ in a subject comprising:
a) an imaging system comprising:
i) an imaging device for generating a quantitative three-dimensional image of the organ that is represented as voxels, wherein each voxel contains information about the activity of a portion of the organ; and
ii) a computing device operatively connected to the imaging device and to a first display device; and
b) one or more computers operatively connected to the imaging system, comprising one or more processors, a memory unit, and a computer-readable storage medium including computer-readable code that is read by the one or more processors to perform a method comprising the steps of:
i) receiving by the one or more computers the generated three-dimensional organ image;
ii) calculating by the one or more computers a mean of the activity represented by the voxels, wherein voxels representing values at upper and lower extremes are excluded from calculation of the mean;
iii) calculating by the one or more computers a standard deviation of the mean obtained in step ii), wherein voxels representing activity above a certain standard deviation of the mean indicate areas of the organ having increased activity and wherein voxels representing activity below a certain standard deviation of the mean indicate areas of the organ having reduced activity; and
iv) generating by the one or more computers a representation of the organ showing areas of the organ having increased activity and/or reduced activity.
2. The system of claim 1, wherein the method performed by the one or more processors comprises displaying by the one or more computers the generated representation of the organ on a second display device operatively connected to the one or more computers.
3. The system of claim 1, wherein the method performed by the one or more processors comprises transmitting from the one or more computers the generated representation of the organ to the imaging system so as to be displayed on the first display device.
4. The system of claim 1, wherein in step ii) voxels are excluded from the calculation of the mean if the voxels represent values at the upper and lower 5% of the values.
5. The system of claim 1, wherein standard deviation (SD) is calculated in 0.1 SD units between 3.0 SD units below the mean to 3.0 SD units above the mean.
6. The system of claim 1, wherein voxels representing activity above 1.5 SD units above the mean indicate areas of the organ having increased activity and wherein voxels representing activity below 1.5 SD units below the mean indicate areas of the organ having reduced activity.
7. The system of claim 1, wherein voxels from the one side of an organ are compared with corresponding voxels from an opposite side of the same organ.
8. The system of claim 1, wherein voxels from an organ on one side of the body are compared with corresponding voxels from the corresponding organ on the opposite side of the body.
9. The system of claim 1, wherein the image of the organ is obtained using positron emission tomography (PET), functional magnetic resonance imaging (fMRI), diffusion tensor magnetic resonance imaging, magnetic resonance imaging of any form, single photon emission computed tomography (SPECT) magnetic source imaging or optical imaging.
10. The system of claim 1, wherein three dimensional imaging of the organ is obtained using positron emission tomography (PET) in connection with a computed tomography (CT) X-ray scan.
11. The system of claim 1, wherein the image of the organ is obtained using positron emission tomography (PET) in connection with any magnetic resonance scan.
12. The system of claim 1, wherein areas of increased or reduced activity in the organ indicate a disease, an injury, a response to an injury, or functional changes in areas that have been disconnected from the remainder of the brain or spinal cord because of injury to connective structures.
13. The system of claim 12, wherein the disease or injury is a tumor, stroke, infection, demyelinating disease, degenerative disease, dementia, ischemia, traumatic injury, shock wave injury, or primary or metastatic cancer.
14. The system of claim 12, wherein the organ is the brain and areas of reduced activity in the organ represent diffuse axonal injury.
15. The system of claim 1 comprising determining a ratio of a number of voxels showing increased activity to a number of voxels showing decreased activity within an area of disease or injury.
16. The system of claim 1 comprising determining a ratio of a number of voxels showing increased activity to a number of voxels showing decreased activity at a border region between an area of disease or injury and normal tissue.
17. The system of claim 1, wherein an image of the organ is obtained and analyzed at a plurality of time points.
18. The system of claim 17, wherein images at different time points are used to evaluate effectiveness of a course of treatment of a subject or to evaluate progression of disease.
19. A system for assessing the activity of an organ in a subject comprising:
one or more computing devices comprising one or more processors, a memory unit, and a computer-readable storage medium including computer-readable code that is read by the one or more processors to perform a method comprising the steps of:
i) obtaining by the one or more computing devices a quantitative three-dimensional image of the organ that is represented as voxels, wherein each voxel contains information about the activity of a portion of the organ generated by an imaging device;
ii) transmitting the generated three-dimensional organ image to one or more analysis computing devices;
iii) obtaining a representation of the organ from the one or more analysis computing devices, wherein the representation shows areas of the organ having increased activity and/or reduced activity; and
iv) displaying the obtained representation on the display device.
20. The system of claim 19, wherein the representation of the organ was generated using the transmitted three-dimensional organ image at the one or more analysis computers by a method comprising the steps of:
i) calculating a mean of the activity represented by the voxels of the three-dimensional organ image, wherein voxels representing values at upper and lower extremes are excluded from calculation of the mean; and
ii) calculating a standard deviation of the mean obtained in step i), wherein voxels representing activity above a certain standard deviation of the mean indicate areas of the organ having increased activity and wherein voxels representing activity below a certain standard deviation of the mean indicate areas of the organ having reduced activity.
US13/494,429 2011-06-17 2012-06-12 Methods and apparatus for assessing activity of an organ and uses thereof Abandoned US20120323108A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/494,429 US20120323108A1 (en) 2011-06-17 2012-06-12 Methods and apparatus for assessing activity of an organ and uses thereof
US13/495,222 US8938102B2 (en) 2011-06-17 2012-06-13 Methods and apparatus for assessing activity of an organ and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161498243P 2011-06-17 2011-06-17
US13/494,429 US20120323108A1 (en) 2011-06-17 2012-06-12 Methods and apparatus for assessing activity of an organ and uses thereof
US13/494,262 US9025845B2 (en) 2011-06-17 2012-06-12 Methods and apparatus for assessing activity of an organ and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13/494,262 Continuation US9025845B2 (en) 2011-06-17 2012-06-12 Methods and apparatus for assessing activity of an organ and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/495,222 Continuation US8938102B2 (en) 2011-06-17 2012-06-13 Methods and apparatus for assessing activity of an organ and uses thereof

Publications (1)

Publication Number Publication Date
US20120323108A1 true US20120323108A1 (en) 2012-12-20

Family

ID=47353701

Family Applications (3)

Application Number Title Priority Date Filing Date
US13/494,262 Active 2032-09-01 US9025845B2 (en) 2011-06-17 2012-06-12 Methods and apparatus for assessing activity of an organ and uses thereof
US13/494,429 Abandoned US20120323108A1 (en) 2011-06-17 2012-06-12 Methods and apparatus for assessing activity of an organ and uses thereof
US13/495,222 Expired - Fee Related US8938102B2 (en) 2011-06-17 2012-06-13 Methods and apparatus for assessing activity of an organ and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US13/494,262 Active 2032-09-01 US9025845B2 (en) 2011-06-17 2012-06-12 Methods and apparatus for assessing activity of an organ and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/495,222 Expired - Fee Related US8938102B2 (en) 2011-06-17 2012-06-13 Methods and apparatus for assessing activity of an organ and uses thereof

Country Status (3)

Country Link
US (3) US9025845B2 (en)
EP (1) EP2740073B1 (en)
WO (1) WO2012173976A2 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120321152A1 (en) * 2011-06-17 2012-12-20 Carroll Robert G Methods and apparatus for assessing activity of an organ and uses thereof
WO2015057315A1 (en) * 2013-09-04 2015-04-23 Kelly Joseph Michael Lawless Methods and systems for the detection of disease
US20150342552A1 (en) * 2013-09-25 2015-12-03 Richard R. Black Patient-specific analysis of raw positron emission tomography data
US9649079B1 (en) * 2014-10-09 2017-05-16 General Electric Company System and method to illustrate a radiation dose applied to different anatomical stages of an exposed subject
US20180018767A1 (en) * 2016-07-12 2018-01-18 National Tsing Hua University Method of segmenting single neuron images with high-dynamic-range thresholds and computer readable storage medium thereof
CN108154532A (en) * 2018-01-25 2018-06-12 北京雅森科技发展有限公司 A kind of method of aided assessment SPECT image thyroid volumes
US11273283B2 (en) 2017-12-31 2022-03-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
US11452839B2 (en) 2018-09-14 2022-09-27 Neuroenhancement Lab, LLC System and method of improving sleep
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US11723579B2 (en) 2017-09-19 2023-08-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement
US11730368B1 (en) * 2022-02-22 2023-08-22 NEUROPHET Inc. Apparatus and method for providing Alzheimer's diagnosis assistance information using MRI and PET imaging

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9135693B2 (en) * 2010-05-18 2015-09-15 Skin Of Mine Dot Com, Llc Image calibration and analysis
EP2940587A4 (en) * 2012-12-28 2016-08-24 Hitachi Ltd Computer, control device for computer system, and recording medium
US20140275960A1 (en) * 2013-03-13 2014-09-18 David R. Hubbard Functional magnetic resonance imaging biomarker of neural abnormality
ES2518690B1 (en) * 2013-12-23 2015-09-29 Centro De Investigación Biomédica En Red De Salud Mental (Cibersam) Method for detecting abnormal areas in the brain from magnetic resonance imaging
GB2558924B (en) 2017-01-20 2021-08-11 Perspectum Diagnostics Ltd Method and apparatus for providing a quantitative volumetric assessment of organ health
CN112241962B (en) * 2020-10-19 2022-07-26 国网河南省电力公司电力科学研究院 Method and system for calculating propagation speed of laser wave generated by discharge
CN115018836A (en) * 2022-08-08 2022-09-06 四川大学 Automatic dividing and predicting method, system and equipment for epileptic focus

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045791A1 (en) * 2001-06-25 2003-03-06 Carroll Timothy J. Determination of the arterial input function in dynamic contrast-enhanced mri
US20050273017A1 (en) * 2004-03-26 2005-12-08 Evian Gordon Collective brain measurement system and method
US20060052685A1 (en) * 2004-09-06 2006-03-09 Cho Zang H PET - MRI hybrid apparatus and method of implementing the same
US20060241382A1 (en) * 2005-03-18 2006-10-26 The Mcw Research Foundation, Inc. MRI method for producing an index indicative of brain disorders
US20080021502A1 (en) * 2004-06-21 2008-01-24 The Trustees Of Columbia University In The City Of New York Systems and methods for automatic symmetry identification and for quantification of asymmetry for analytic, diagnostic and therapeutic purposes
US20090252391A1 (en) * 2005-08-22 2009-10-08 National Center Of Neurology And Psychiatry Method for assisting in diagnosis of cerebral diseases and apparatus thereof
US20090318794A1 (en) * 2002-07-26 2009-12-24 Decharms Richard Christopher Methods for measurement and analysis of brain activity

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4922915A (en) * 1987-11-27 1990-05-08 Ben A. Arnold Automated image detail localization method
US4881032A (en) 1988-10-21 1989-11-14 General Electric Company Method of, and apparatus for, NMR spectroscopic metabolite imaging and quantification
US5225781A (en) 1990-08-10 1993-07-06 General Electric Company Robust decomposition of NMR images by chemical species
US5844241A (en) 1996-07-19 1998-12-01 City Of Hope System and method for determining internal radioactivity and absorbed dose estimates
WO2000062247A1 (en) 1999-04-13 2000-10-19 Chromavision Medical Systems, Inc. Histological reconstruction and automated image analysis
US7088854B2 (en) 2001-04-25 2006-08-08 Cotman Carl W Method and apparatus for generating special-purpose image analysis algorithms
US20030036083A1 (en) 2001-07-19 2003-02-20 Jose Tamez-Pena System and method for quantifying tissue structures and their change over time
DK2793189T3 (en) * 2001-10-03 2017-02-06 Retinalyze As Assessment of lesions in an image
WO2003046833A2 (en) 2001-11-24 2003-06-05 Image Analysis, Inc. Automatic detection and quantification of coronary and aortic calcium
US6658080B1 (en) * 2002-08-05 2003-12-02 Voxar Limited Displaying image data using automatic presets
EP1595205B1 (en) * 2002-10-28 2018-04-25 The General Hospital Corporation Tissue disorder imaging analysis
AU2004203173A1 (en) 2003-07-14 2005-02-03 Sunnybrook And Women's College And Health Sciences Centre Optical image-based position tracking for magnetic resonance imaging
US20050085705A1 (en) * 2003-10-21 2005-04-21 Rao Stephen M. fMRI system for use in detecting neural abnormalities associated with CNS disorders and assessing the staging of such disorders
US20050113680A1 (en) 2003-10-29 2005-05-26 Yoshihiro Ikeda Cerebral ischemia diagnosis assisting apparatus, X-ray computer tomography apparatus, and apparatus for aiding diagnosis and treatment of acute cerebral infarct
US20060241718A1 (en) 2003-11-26 2006-10-26 Wicab, Inc. Systems and methods for altering brain and body functions and for treating conditions and diseases of the same
US7907759B2 (en) 2006-02-02 2011-03-15 Wake Forest University Health Sciences Cardiac visualization systems for displaying 3-D images of cardiac voxel intensity distributions with optional physician interactive boundary tracing tools
US7747308B2 (en) 2004-02-06 2010-06-29 Wake Forest University Health Sciences Non-invasive systems and methods for the determination of cardiac injury using a characterizing portion of a voxel histogram
US7315639B2 (en) 2004-03-03 2008-01-01 Mevis Gmbh Method of lung lobe segmentation and computer system
US7430313B2 (en) 2004-05-04 2008-09-30 Zbilut Joseph P Methods using recurrence quantification analysis to analyze and generate images
WO2005114229A2 (en) * 2004-05-14 2005-12-01 The General Hospital Corporation Perfusion weighted mri with local arterial input functions
US7868884B2 (en) * 2004-08-31 2011-01-11 General Electric Company System and method for generating a digital image of an internal anatomy of a person
US7127095B2 (en) 2004-10-15 2006-10-24 The Brigham And Women's Hospital, Inc. Factor analysis in medical imaging
US20060114254A1 (en) * 2004-11-26 2006-06-01 Tim Day Volume rendering apparatus and method
WO2006104468A1 (en) * 2005-03-31 2006-10-05 Agency For Science, Technology And Research Method and apparatus for image segmentation
US7702141B2 (en) 2005-06-29 2010-04-20 General Electric Company Method for quantifying an object in a larger structure using a reconstructed image
US7876938B2 (en) 2005-10-06 2011-01-25 Siemens Medical Solutions Usa, Inc. System and method for whole body landmark detection, segmentation and change quantification in digital images
WO2007042553A1 (en) 2005-10-13 2007-04-19 Evotec Technologies Gmbh Method for detecting contours in images of biological cells
US8077937B2 (en) 2005-11-18 2011-12-13 Cornell University Reproducible objective quantification method to segment white matter structures
US8263043B2 (en) 2006-04-14 2012-09-11 Carnegie Mellon University Cellular labeling and quantification for nuclear magnetic resonance techniques
GB0609610D0 (en) 2006-05-15 2006-06-21 Stiftelsen Universitetsforskni MR perfusion
EP1865464B1 (en) 2006-06-08 2013-11-20 National University Corporation Kobe University Processing device and program product for computer-aided image based diagnosis
WO2008017984A2 (en) 2006-08-09 2008-02-14 Koninklijke Philips Electronics N.V. A method, apparatus, graphical user interface, computer-readable medium, and use for quantification of a structure in an object of an image dataset
US8125484B2 (en) * 2006-11-10 2012-02-28 General Electric Company Method, apparatus and user interface for determining an arterial input function used for calculating hemodynamic parameters
US8099149B2 (en) 2006-11-20 2012-01-17 Northwestern University MRI method for quantification of cerebral perfusion
US7860331B2 (en) 2006-11-23 2010-12-28 General Electric Company Purpose-driven enhancement filtering of anatomical data
US7848557B2 (en) 2007-03-23 2010-12-07 University Of Utah Research Foundation Rapid multi-tracer PET imaging systems and methods
US8068650B2 (en) 2007-03-30 2011-11-29 Siemens Information Systems, Ltd. Lesion quantification and tracking using multiple modalities
US7813538B2 (en) * 2007-04-17 2010-10-12 University Of Washington Shadowing pipe mosaicing algorithms with application to esophageal endoscopy
US8918162B2 (en) * 2007-04-17 2014-12-23 Francine J. Prokoski System and method for using three dimensional infrared imaging to provide psychological profiles of individuals
CN101784907A (en) * 2007-04-30 2010-07-21 皇家飞利浦电子股份有限公司 Positive contrast MR susceptibility imaging
WO2008144751A1 (en) * 2007-05-21 2008-11-27 Cornell University Method for segmenting objects in images
US8229201B2 (en) 2007-06-15 2012-07-24 General Electric Company Systems, methods and apparatus for plaque visualization and quantification using fuzzy and adaptive region classes
US8355552B2 (en) 2007-06-20 2013-01-15 The Trustees Of Columbia University In The City Of New York Automated determination of lymph nodes in scanned images
DE102007043731A1 (en) * 2007-09-13 2009-04-02 Siemens Ag Medical image recording device, in particular for the production of image recordings in the context of a treatment of cardiac arrhythmias, and associated method
EP2194836B1 (en) 2007-09-25 2015-11-04 Perception Raisonnement Action En Medecine Apparatus for assisting cartilage diagnostic and therapeutic procedures
US8000769B2 (en) 2007-10-24 2011-08-16 Wisconsin Alumni Research Foundation Methods for fat quantification with correction for noise bias
EP2205157B1 (en) 2007-11-06 2017-06-07 Koninklijke Philips N.V. System for quantification of neovasculature in ct volumes
US20100259263A1 (en) 2007-11-14 2010-10-14 Dominic Holland Longitudinal registration of anatomy in magnetic resonance imaging
CN101919230B (en) 2007-12-25 2013-02-13 梅迪奇视觉-脑科技有限公司 Noise reduction of images
US7692424B2 (en) 2008-02-28 2010-04-06 Magnetic Resonance Innovations, Inc. Method of and software application for quantifying objects in magnetic resonance images via multiple complex summations
US8781197B2 (en) 2008-04-28 2014-07-15 Cornell University Tool for accurate quantification in molecular MRI
US8032335B2 (en) 2008-05-02 2011-10-04 Emory University Evaluating magnetic resonance spectra
WO2009146388A1 (en) * 2008-05-28 2009-12-03 The Trustees Of Columbia University In The City Of New York Voxel-based methods for assessing subjects using positron emission tomography
JP5243865B2 (en) 2008-07-07 2013-07-24 浜松ホトニクス株式会社 Brain disease diagnosis system
US20100074480A1 (en) * 2008-09-22 2010-03-25 University Of Washington Device for generating alternative of normal brain database
AU2009294085B2 (en) * 2008-09-22 2013-08-22 Nihon Medi-Physics Co., Ltd. Device for creating database of alternative normal brain
US8285066B2 (en) 2008-12-05 2012-10-09 General Electric Company System and method for generating high resolution images
US8970578B2 (en) 2008-12-19 2015-03-03 Szilard Voros System and method for lesion-specific coronary artery calcium quantification
US8768016B2 (en) 2009-06-19 2014-07-01 Carestream Health, Inc. Method for quantifying caries
US20110054295A1 (en) * 2009-08-25 2011-03-03 Fujifilm Corporation Medical image diagnostic apparatus and method using a liver function angiographic image, and computer readable recording medium on which is recorded a program therefor
US20110077503A1 (en) * 2009-08-25 2011-03-31 Medical University Of South Carolina Automatic MRI Quantification of Structural Body Abnormalities
US20110150309A1 (en) 2009-11-27 2011-06-23 University Health Network Method and system for managing imaging data, and associated devices and compounds
US8849000B2 (en) * 2009-12-04 2014-09-30 Shenzhen Institute Of Advanced Technology, Chinese Academy Of Sciences Method and device for detecting bright brain regions from computed tomography images
WO2012071584A2 (en) 2010-11-26 2012-05-31 Brigham And Women's Hospital, Inc. Method for assessing repetitive head injuries with tow-dimensional magnetic resonance spectorscopy
BR112013017073A2 (en) * 2011-01-05 2018-06-05 Koninl Philips Electronics Nv apparatus for detecting asymmetry in an object, method for detecting asymmetry, computer readable medium having a software and system for detecting brain diseases.
US9557433B2 (en) * 2011-03-23 2017-01-31 Seismic Global Ambient, Llc Fracture imaging methods employing skeletonization of seismic emission tomography data
US9442205B2 (en) * 2011-03-23 2016-09-13 Global Ambient Seismic, Inc. Method for assessing the effectiveness of modifying transmissive networks of natural reservoirs
US9025845B2 (en) 2011-06-17 2015-05-05 Quantitative Imaging, Inc. Methods and apparatus for assessing activity of an organ and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045791A1 (en) * 2001-06-25 2003-03-06 Carroll Timothy J. Determination of the arterial input function in dynamic contrast-enhanced mri
US20090318794A1 (en) * 2002-07-26 2009-12-24 Decharms Richard Christopher Methods for measurement and analysis of brain activity
US20050273017A1 (en) * 2004-03-26 2005-12-08 Evian Gordon Collective brain measurement system and method
US20080021502A1 (en) * 2004-06-21 2008-01-24 The Trustees Of Columbia University In The City Of New York Systems and methods for automatic symmetry identification and for quantification of asymmetry for analytic, diagnostic and therapeutic purposes
US20060052685A1 (en) * 2004-09-06 2006-03-09 Cho Zang H PET - MRI hybrid apparatus and method of implementing the same
US20060241382A1 (en) * 2005-03-18 2006-10-26 The Mcw Research Foundation, Inc. MRI method for producing an index indicative of brain disorders
US20090252391A1 (en) * 2005-08-22 2009-10-08 National Center Of Neurology And Psychiatry Method for assisting in diagnosis of cerebral diseases and apparatus thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Pujara (Understanding feature selection in functional magnetic resonance imaging, 2005). *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120321152A1 (en) * 2011-06-17 2012-12-20 Carroll Robert G Methods and apparatus for assessing activity of an organ and uses thereof
US8938102B2 (en) * 2011-06-17 2015-01-20 Quantitative Imaging, Inc. Methods and apparatus for assessing activity of an organ and uses thereof
US9025845B2 (en) 2011-06-17 2015-05-05 Quantitative Imaging, Inc. Methods and apparatus for assessing activity of an organ and uses thereof
WO2015057315A1 (en) * 2013-09-04 2015-04-23 Kelly Joseph Michael Lawless Methods and systems for the detection of disease
US11382586B2 (en) * 2013-09-25 2022-07-12 Richard R. Black Patient-specific analysis of raw positron emission tomography data
US20150342552A1 (en) * 2013-09-25 2015-12-03 Richard R. Black Patient-specific analysis of raw positron emission tomography data
US9649079B1 (en) * 2014-10-09 2017-05-16 General Electric Company System and method to illustrate a radiation dose applied to different anatomical stages of an exposed subject
US20180018767A1 (en) * 2016-07-12 2018-01-18 National Tsing Hua University Method of segmenting single neuron images with high-dynamic-range thresholds and computer readable storage medium thereof
US10002425B2 (en) * 2016-07-12 2018-06-19 National Tsing Hua University Method of segmenting single neuron images with high-dynamic-range thresholds and computer readable storage medium thereof
US11723579B2 (en) 2017-09-19 2023-08-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US11478603B2 (en) 2017-12-31 2022-10-25 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11318277B2 (en) 2017-12-31 2022-05-03 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11273283B2 (en) 2017-12-31 2022-03-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
CN108154532A (en) * 2018-01-25 2018-06-12 北京雅森科技发展有限公司 A kind of method of aided assessment SPECT image thyroid volumes
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
US11452839B2 (en) 2018-09-14 2022-09-27 Neuroenhancement Lab, LLC System and method of improving sleep
US11730368B1 (en) * 2022-02-22 2023-08-22 NEUROPHET Inc. Apparatus and method for providing Alzheimer's diagnosis assistance information using MRI and PET imaging

Also Published As

Publication number Publication date
EP2740073A2 (en) 2014-06-11
US9025845B2 (en) 2015-05-05
US20120321152A1 (en) 2012-12-20
US8938102B2 (en) 2015-01-20
EP2740073A4 (en) 2015-08-05
US20120321160A1 (en) 2012-12-20
WO2012173976A3 (en) 2014-05-08
WO2012173976A2 (en) 2012-12-20
EP2740073B1 (en) 2017-01-18

Similar Documents

Publication Publication Date Title
US9025845B2 (en) Methods and apparatus for assessing activity of an organ and uses thereof
Fox et al. Location-probability profiles for the mouth region of human primary motor–sensory cortex: model and validation
Liu et al. Cortical thinning in patients with recent onset post-traumatic stress disorder after a single prolonged trauma exposure
Biederman et al. Towards further understanding of the co-morbidity between attention deficit hyperactivity disorder and bipolar disorder: a MRI study of brain volumes
Shah et al. Chronic, treatment-resistant depression and right fronto-striatal atrophy
Suchan et al. Reduction of gray matter density in the extrastriate body area in women with anorexia nervosa
ES2414614T3 (en) Tools to help diagnose neurodegenerative diseases
US8676294B2 (en) Brain disease diagnosis system
Kim et al. Cortical asymmetries in normal, mild cognitive impairment, and Alzheimer's disease
US20050215889A1 (en) Methods for using pet measured metabolism to determine cognitive impairment
Rais et al. Brain volume reductions in medication-naive patients with schizophrenia in relation to intelligence quotient
US10991095B2 (en) Systems and methods for computation of functional index parameter values for blood vessels
JP2014508340A (en) Automatic quantification of asymmetry
Shiga et al. Assessment of olfactory nerve by SPECT-MRI image with nasal thallium-201 administration in patients with olfactory impairments in comparison to healthy volunteers
WO2015085320A1 (en) Methods and systems for analyzing anatomy from multiple granularity levels
Csernansky et al. Symmetric abnormalities in sulcal patterning in schizophrenia
Li et al. Abnormal surface morphology of the central sulcus in children with attention-deficit/hyperactivity disorder
Sun et al. Automated template-based PET region of interest analyses in the aging brain
Cabrera et al. Neuroanatomical features and its usefulness in classification of patients with PANDAS
AU2009294085A1 (en) Device for creating database of alternative normal brain
US8396266B2 (en) Characterisation of functional medical image scans
Karbe et al. Cerebral networks and functional brain asymmetry: evidence from regional metabolic changes during word repetition
Brinkmann et al. Statistical parametric mapping demonstrates asymmetric uptake with Tc-99m ECD and Tc-99m HMPAO SPECT in normal brain
Aubert-Broche et al. Detection of inter-hemispheric asymmetries of brain perfusion in SPECT
Liu et al. Deep learning substitutes gadolinium in detecting functional and structural brain lesions with MRI

Legal Events

Date Code Title Description
AS Assignment

Owner name: QUANTITATIVE IMAGING, INC., FLORIDA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CARROLL, ROBERT G.;REEL/FRAME:028399/0791

Effective date: 20120614

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION